Immunosenescence: Molecular Mechanisms, Diseases, and Therapeutic Innovations

Abstract

Immunosenescence denotes progressive deterioration of immune system during physiological aging, initially recognized by the observation of heightened susceptibility to diverse pathologies in elder population. Beyond exhibiting canonical cellular senescence features, senescent immune cells manifest multidimensional dysfunction characterized by impaired secretory capacity and functional disorders. This process further triggers systemic epigenetic dysregulation and failure in damage repair, which collectively remodel metabolic and inflammatory microenvironments to attenuate immune responses and elevate risks of diverse degenerative diseases or multiple types of cancer. Critically, senescence-associated secretory phenotype (SASP) factors secreted by senescent cells display profound disease-associated content and spatial–temporal heterogeneity, engaging in bidirectional crosstalk with pathological progression through interconnected signaling axes. Reciprocally, both pathogenic evolution and therapeutic pressures are confirmed to exacerbate immunosenescence, driving impaired replenishment of immune cells and pathological accumulation of immunosuppressive factors that impact disease progression and poor outcomes. As indicated by clinical evidence, senotherapies designed to eliminate senescent cells or block SASP signaling have emerged as promising interventions to ameliorate age-related pathologies. In this review, we systematically combed and delineated disease-specific immunosenescent hallmarks, dissect disease–immunosenescence interplay patterns, and evaluated the translational value of immunosenescence-targeting strategies.

Keywords

chronic inflammation / hypoxia / immunosenescence / immunotherapy / SASP / tumor-induced senescence

References

[1] G. Pawelec, “Age and Immunity: What Is "Immunosenescence"?,” Experimental Gerontology 105 (2018): 4–9.

[2] Z. Liu, Q. Liang, Y. Ren, et al., “Immunosenescence: Molecular Mechanisms and Diseases,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 200.

[3] R. Di Micco, V. Krizhanovsky, D. Baker, and F. d'Adda di Fagagna, “Cellular Senescence in Ageing: From Mechanisms to Therapeutic Opportunities,” Nature Reviews Molecular Cell Biology 22, no. 2 (2021): 75–95.

[4] B. G. Childs, M. Gluscevic, D. J. Baker, et al., “Senescent Cells: An Emerging Target for Diseases of Ageing,” Nature Reviews Drug Discovery 16, no. 10 (2017): 718–735.

[5] N. S. Mohamad Kamal, S. Safuan, S. Shamsuddin, and P. Foroozandeh, “Aging of the Cells: Insight Into Cellular Senescence and Detection Methods,” European Journal of Cell Biology 99, no. 6 (2020): 151108.

[6] D. McHugh and J. Gil, “Senescence and Aging: Causes, Consequences, and Therapeutic Avenues,” Journal of Cell Biology 217, no. 1 (2018): 65–77.

[7] N. Kudlova, J. B. De Sanctis, and M. Hajduch, “Cellular Senescence: Molecular Targets, Biomarkers, and Senolytic Drugs,” International Journal of Molecular Sciences 23, no. 8 (2022): 4168.

[8] V. Suryadevara, A. D. Hudgins, A. Rajesh, et al., “SenNet Recommendations for Detecting Senescent Cells in Different Tissues,” Nature Reviews Molecular Cell Biology 25, no. 12 (2024): 1001–1023.

[9] M. Bourdens, Y. Jeanson, M. Taurand, et al., “Short Exposure to Cold Atmospheric Plasma Induces Senescence in human Skin Fibroblasts and Adipose Mesenchymal Stromal Cells,” Scientific Reports 9, no. 1 (2019): 8671.

[10] V. Suryadevara, A. D. Hudgins, A. Rajesh, et al., “SenNet Recommendations for Detecting Senescent Cells in Different Tissues,” Nature Reviews Molecular Cell Biology 25, no. 12 (2024): 1001–1023.

[11] M. Alorda-Clara, M. Torrens-Mas, P. M. Morla-Barcelo, et al., “High Concentrations of Genistein Decrease Cell Viability Depending on Oxidative Stress and Inflammation in Colon Cancer Cell Lines,” International Journal of Molecular Sciences 23, no. 14 (2022): 7526.

[12] Z. Liu, Q. Ji, J. Ren, et al., “Large-scale Chromatin Reorganization Reactivates Placenta-specific Genes That Drive Cellular Aging,” Developmental Cell 57, no. 11 (2022): 1347–1368.

[13] S. W. Criscione, M. De Cecco, B. Siranosian, et al., “Reorganization of Chromosome Architecture in Replicative Cellular Senescence,” Science Advances 2, no. 2 (2016): e1500882.

[14] S. Victorelli, H. Salmonowicz, J. Chapman, et al., “Apoptotic Stress Causes mtDNA Release During Senescence and Drives the SASP,” Nature 622, no. 7983 (2023): 627–636.

[15] E. L. James, R. D. Michalek, G. N. Pitiyage, et al., “Senescent human Fibroblasts Show Increased Glycolysis and Redox Homeostasis With Extracellular Metabolomes That Overlap With Those of Irreparable DNA Damage, Aging, and Disease,” Journal of Proteome Research 14, no. 4 (2015): 1854–1871.

[16] X. Dou, Q. Fu, Q. Long, et al., “PDK4-dependent Hypercatabolism and Lactate Production of Senescent Cells Promotes Cancer Malignancy,” Nature Metabolism 5, no. 11 (2023): 1887–1910.

[17] K. Roh, J. Noh, Y. Kim, et al., “Lysosomal Control of Senescence and Inflammation Through Cholesterol Partitioning,” Nature Metabolism 5, no. 3 (2023): 398–413.

[18] D. V. Ziegler, J. Czarnecka-Herok, M. Vernier, et al., “Cholesterol Biosynthetic Pathway Induces Cellular Senescence Through ERRα,” NPJ Aging 10, no. 1 (2024): 5.

[19] H. Zhu, Q. Li, T. Liao, et al., “Metabolomic Profiling of Single Enlarged Lysosomes,” Nature Methods 18, no. 7 (2021): 788–798.

[20] Z. Bai, P. Yang, F. Yu, et al., “Combining Adoptive NK Cell Infusion With a Dopamine-releasing Peptide Reduces Senescent Cells in Aged Mice,” Cell Death & Disease 13, no. 4 (2022): 305.

[21] S. Kaushik, I. Tasset, E. Arias, et al., “Autophagy and the Hallmarks of Aging,” Ageing Research Reviews 72 (2021): 101468.

[22] L. Zhang, X. Chen, S. Zu, and Y. Lu, “Characteristics of Circulating Adaptive Immune Cells in Patients With Colorectal Cancer,” Scientific Reports 12, no. 1 (2022): 18166.

[23] S. Pei, X. Deng, R. Yang, et al., “Age-related Decline in CD8(+) Tissue Resident Memory T Cells Compromises Antitumor Immunity,” Nature Aging 4, no. 12 (2024): 1828–1844.

[24] B. A. Barajas-Gomez, O. Rosas-Carrasco, S. L. Morales-Rosales, et al., “Relationship of Inflammatory Profile of Elderly Patients Serum and Senescence-associated Secretory Phenotype With human Breast Cancer Cells Proliferation: Role of IL6/IL8 Ratio,” Cytokine 91 (2017): 13–29.

[25] Q. Wei, R. Chen, X. He, et al., “Multi-omics and Single Cell Characterization of Cancer Immunosenescence Landscape,” Scientific Data 11, no. 1 (2024): 739.

[26] X. Ming, Z. Yang, Y. Huang, et al., “A Chimeric Peptide Promotes Immune Surveillance of Senescent Cells in Injury, Fibrosis, Tumorigenesis and Aging,” Nature Aging 5, no. 1 (2025): 28–47.

[27] L. Zhu, L. Zhang, J. Qi, Z. Ye, G. Nie, and S. Leng, “Machine Learning-derived Immunosenescence Index for Predicting Outcome and Drug Sensitivity in Patients With Skin Cutaneous Melanoma,” Genes and Immunity 25, no. 3 (2024): 219–231.

[28] Y. Wang, R. Li, R. Tong, et al., “Integrating Single-cell RNA and T Cell/B Cell Receptor Sequencing With Mass Cytometry Reveals Dynamic Trajectories of human Peripheral Immune Cells From Birth to Old Age,” Nature Immunology 26, no. 2 (2025): 308–322.

[29] W. Li, Z. Zhang, S. Kumar, et al., “Single-cell Immune Aging Clocks Reveal Inter-individual Heterogeneity During Infection and Vaccination,” Nature Aging 5, no. 4 (2025): 607–621.

[30] H. Li, W. Zhao, F. Yang, et al., “Immunosenescence Inventory-a Multi-omics Database for Immune Aging Research,” Nucleic Acids Research 53, no. D1 (2025): D1047–D1054.

[31] H. Huang, Y. Chen, W. Xu, et al., “Decoding Aging Clocks: New Insights From Metabolomics,” Cell Metabolism 37, no. 1 (2025): 34–58.

[32] Z. Zhang, S. R. Reynolds, H. G. Stolrow, J. Q. Chen, B. C. Christensen, and L. A. Salas, “Deciphering the Role of Immune Cell Composition in Epigenetic Age Acceleration: Insights From Cell-type Deconvolution Applied to human Blood Epigenetic Clocks,” Aging Cell 23, no. 3 (2024): e14071.

[33] A. Alpert, Y. Pickman, M. Leipold, et al., “A Clinically Meaningful Metric of Immune Age Derived From High-dimensional Longitudinal Monitoring,” Nature Medicine 25, no. 3 (2019): 487–495.

[34] Y. Xia, W. Li, Y. Li, et al., “The Clinical Value of the Changes of Peripheral Lymphocyte Subsets Absolute Counts in Patients With Non-small Cell Lung Cancer,” Translational Oncology 13, no. 12 (2020): 100849.

[35] A. Arvey, M. Rowe, J. B. Legutki, et al., “Age-associated Changes in the Circulating human Antibody Repertoire Are Upregulated in Autoimmunity,” Immunity & Ageing: I & A 17 (2020): 28.

[36] N. Sayed, Y. Huang, K. Nguyen, et al., “An Inflammatory Aging Clock (iAge) Based on Deep Learning Tracks Multimorbidity, Immunosenescence, Frailty and Cardiovascular Aging,” Nature Aging 1 (2021): 598–615.

[37] S. Rutella, J. Vadakekolathu, F. Mazziotta, et al., “Immune Dysfunction Signatures Predict Outcomes and Define Checkpoint Blockade-unresponsive Microenvironments in Acute Myeloid Leukemia,” The Journal of Clinical Investigation 132, no. 21 (2022): e159579.

[38] Z. Jia, Z. Ren, D. Ye, et al., “Immune-Ageing Evaluation of Peripheral T and NK Lymphocyte Subsets in Chinese Healthy Adults,” Phenomics (Cham, Switzerland) 3, no. 4 (2023): 360–374.

[39] H. S. Oh, J. Rutledge, D. Nachun, et al., “Organ Aging Signatures in the Plasma Proteome Track Health and Disease,” Nature 624, no. 7990 (2023): 164–172.

[40] A. Tomusiak, A. Floro, R. Tiwari, et al., “Development of an Epigenetic Clock Resistant to Changes in Immune Cell Composition,” Communications Biology 7, no. 1 (2024): 934.

[41] S. Y. Lu, Q. C. Xu, D. L. Fang, et al., “Turning to Immunosuppressive Tumors: Deciphering the Immunosenescence-related Microenvironment and Prognostic Characteristics in Pancreatic Cancer, in Which GLUT1 Contributes to Gemcitabine Resistance,” Heliyon 10, no. 17 (2024): e36684.

[42] J. J. Domínguez-Del-Castillo, P. Álvarez-Heredia, and I. Reina-Alfonso, “Divergent Immune Pathways in Coronary Artery Disease and Aortic Stenosis: The Role of Chronic Inflammation and Senescence,” International Journal of Molecular Sciences 26, no. 11 (2025): 5248.

[43] M. Fuentealba, L. Rouch, S. Guyonnet, et al., “A Blood-based Epigenetic Clock for Intrinsic Capacity Predicts Mortality and Is Associated With Clinical, Immunological and Lifestyle Factors,” Nature Aging 5, no. 7 (2025): 1207–1216.

[44] H. S. Oh, Y. Le Guen, N. Rappoport, et al., “Plasma Proteomics Links Brain and Immune System Aging With Healthspan and Longevity,” Nature Medicine 31, no. 8 (2025): 2703–2711.

[45] A. Kalyakulina, I. Yusipov, A. Trukhanov, C. Franceschi, A. Moskalev, and M. Ivanchenko, “EpInflammAge: Epigenetic-Inflammatory Clock for Disease-Associated Biological Aging Based on Deep Learning,” International Journal of Molecular Sciences 26, no. 13 (2025): 6284.

[46] B. Olinger, R. Banarjee, A. Dey, et al., “The Secretome of Senescent Monocytes Predicts Age-related Clinical Outcomes in Humans,” Nature Aging 5, no. 7 (2025): 1266–1279.

[47] A. Kulikowska de Nałęcz, L. Ciszak, and L. Usnarska-Zubkiewicz, “Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors,” International Journal of Molecular Sciences 24, no. 6 (2023): 5730.

[48] H. Suen, R. Brown, S. Yang, et al., “Multiple Myeloma Causes Clonal T-cell Immunosenescence: Identification of Potential Novel Targets for Promoting Tumour Immunity and Implications for Checkpoint Blockade,” Leukemia 30, no. 8 (2016): 1716–1724.

[49] D. J. Chung, K. B. Pronschinske, J. A. Shyer, et al., “T-cell Exhaustion in Multiple Myeloma Relapse After Autotransplant: Optimal Timing of Immunotherapy,” Cancer Immunology Research 4, no. 1 (2016): 61–71.

[50] X. Xu, F. Wei, L. Xiao, et al., “High Proportion of Circulating CD8 + CD28- senescent T Cells Is an Independent Predictor of Distant Metastasis in Nasopharyngeal Canrcinoma After Radiotherapy,” Journal of Translational Medicine 21, no. 1 (2023): 64.

[51] K. A. Thin, P. Angsuwatcharakon, S. W. Edwards, A. Mutirangura, and C. Puttipanyalears, “Upregulation of p16INK4A in Peripheral White Blood Cells as a Novel Screening Marker for Colorectal Carcinoma,” Asian Pacific Journal of Cancer Prevention: APJCP 23, no. 11 (2022): 3753–3761.

[52] Y. Li, Y. Zhao, Y. Gao, et al., “Age-related Macrophage Alterations Are Associated With Carcinogenesis of Colorectal Cancer,” Carcinogenesis 43, no. 11 (2022): 1039–1049.

[53] Q. Wu, B. Brouwers, B. Dalmasso, et al., “Dynamic Alterations of Immunosenescence-related Genes in Older Women With Breast Cancer Receiving Chemotherapy: A Prospective Study,” Translational Oncology 25 (2022): 101527.

[54] Q. Hu, Y. Hong, P. Qi, et al., “Atlas of Breast Cancer Infiltrated B-lymphocytes Revealed by Paired Single-cell RNA-sequencing and Antigen Receptor Profiling,” Nature Communications 12, no. 1 (2021): 2186.

[55] K. H. Kim, H. Pyo, H. Lee, et al., “Association of T Cell Senescence With Radiation Pneumonitis in Patients With Non-small Cell Lung Cancer,” International Journal of Radiation Oncology, Biology, Physics 115, no. 2 (2023): 464–475.

[56] L. I. Prieto, I. Sturmlechner, S. I. Graves, et al., “Senescent Alveolar Macrophages Promote Early-stage Lung Tumorigenesis,” Cancer Cell 41, no. 7 (2023): 1261–1275. e6.

[57] S. Haston, E. Gonzalez-Gualda, S. Morsli, et al., “Clearance of Senescent Macrophages Ameliorates Tumorigenesis in KRAS-driven Lung Cancer,” Cancer Cell 41, no. 7 (2023): 1242–1260. e6.

[58] N. Bancaro, B. Calì, M. Troiani, et al., “Apolipoprotein E Induces Pathogenic Senescent-Like Myeloid Cells in Prostate Cancer,” Cancer Cell 41, no. 3 (2023): 602–619. e11.

[59] D. Bianchi-Frias, M. Damodarasamy, S. A. Hernandez, et al., “The Aged Microenvironment Influences the Tumorigenic Potential of Malignant Prostate Epithelial Cells,” Molecular Cancer Research: MCR 17, no. 1 (2019): 321–331.

[60] Y. C. Lu, C. H. Ho, J. H. Hong, et al., “NKG2A and Circulating Extracellular Vesicles Are Key Regulators of Natural Killer Cell Activity in Prostate Cancer After Prostatectomy,” Molecular Oncology 17, no. 8 (2023): 1613–1627.

[61] D. Dai, Y. Pei, B. Zhu, et al., “Chemoradiotherapy-induced ACKR2(+) Tumor Cells Drive CD8(+) T Cell Senescence and Cervical Cancer Recurrence,” Cell Reports Medicine 5, no. 5 (2024): 101550.

[62] S. Wu, X. Li, F. Hong, et al., “Integrative Analysis of Single-cell Transcriptomics Reveals Age-associated Immune Landscape of Glioblastoma,” Frontiers in Immunology 14 (2023): 1028775.

[63] F. Baychelier, A. Achour, S. Nguyen, et al., “Natural Killer Cell Deficiency in Patients With non-Hodgkin Lymphoma After Lung Transplantation,” Journal of Heart and Lung Transplantation 34, no. 4 (2015): 604–6412.

[64] S. Dupuy, M. Lambert, D. Zucman, et al., “Human Herpesvirus 8 (HHV8) Sequentially Shapes the NK Cell Repertoire During the Course of Asymptomatic Infection and Kaposi Sarcoma,” Plos Pathogens 8, no. 1 (2012): e1002486.

[65] A. Lechner, H. A. Schlößer, M. Thelen, et al., “Tumor-associated B Cells and Humoral Immune Response in Head and Neck Squamous Cell Carcinoma,” Oncoimmunology 8, no. 3 (2019): 1535293.

[66] T. Tsukishiro, A. D. Donnenberg, and T. L. Whiteside, “Rapid Turnover of the CD8(+)CD28(-) T-cell Subset of Effector Cells in the Circulation of Patients With Head and Neck Cancer,” Cancer Immunology, Immunotherapy: CII 52, no. 10 (2003): 599–607.

[67] M. F. van der Kamp, E. Hiddingh, J. de Vries, et al., “Association of Tumor Microenvironment With Biological and Chronological Age in Head and Neck Cancer,” Cancers (Basel) 15, no. 15 (2023): 3834.

[68] J. Zhao, Z. Wang, Y. Tian, J. Ning, and H. Ye, “T Cell Exhaustion and Senescence for Ovarian Cancer Immunotherapy,” Seminars in Cancer Biology 104-105 (2024): 1–15.

[69] A. Gao, X. Liu, W. Lin, et al., “Tumor-derived ILT4 Induces T Cell Senescence and Suppresses Tumor Immunity,” Journal for ImmunoTherapy of Cancer 9, no. 3 (2021): e001536.

[70] J. Pieper, S. Johansson, O. Snir, et al., “Peripheral and Site-specific CD4(+) CD28(null) T Cells From Rheumatoid Arthritis Patients Show Distinct Characteristics,” Scandinavian Journal of Immunology 79, no. 2 (2014): 149–155.

[71] E. Jeong, J. Y. Jung, M. J. Lee, et al., “A Link Between CD8+CD27-CD28- T Cells Expressing chemerin Chemokine-Like Receptor 1 and Rheumatoid Arthritis,” Clinical and Experimental Rheumatology 41, no. 5 (2023): 1105–1113.

[72] J. Jiang, M. Yang, H. Zhu, et al., “CD4(+)CD57(+) senescent T Cells as Promoters of Systemic Lupus Erythematosus Pathogenesis and the Therapeutic Potential of Senolytic BCL-2 Inhibitor,” European Journal of Immunology 54, no. 7 (2024): e2350603.

[73] G. Montoya-Ortiz, “Immunosenescence, Aging, and Systemic Lupus Erythematous,” Autoimmune Diseases 2013 (2013): 267078.

[74] L. Yang and L. Yuan, “The Role and Intrinsic Connection of Cellular Senescence and Cell Death in Inflammatory Bowel Disease,” Frontiers in Cell and Developmental Biology 13 (2025): 1502531.

[75] E. Y. M. Lau, E. C. Carroll, L. A. Callender, et al., “Type 2 Diabetes Is Associated With the Accumulation of Senescent T Cells,” Clinical and Experimental Immunology 197, no. 2 (2019): 205–213.

[76] D. Sui, C. Li, X. Tang, et al., “Sialic Acid-mediated Photochemotherapy Enhances Infiltration of CD8(+) T Cells From Tumor-draining Lymph Nodes Into Tumors of Immunosenescent Mice,” Acta Pharmaceutica Sinica B 13, no. 1 (2023): 425–439.

[77] J. Liu, J. Liu, G. Qin, et al., “MDSCs-derived GPR84 Induces CD8(+) T-cell Senescence via p53 Activation to Suppress the Antitumor Response,” Journal for ImmunoTherapy of Cancer 11, no. 11 (2023): e007802.

[78] X. Liu, C. L. Hartman, L. Li, et al., “Reprogramming Lipid Metabolism Prevents Effector T Cell Senescence and Enhances Tumor Immunotherapy,” Science Translational Medicine 13, no. 587 (2021): eaaz6314.

[79] S. Mahbub, C. R. Deburghgraeve, and E. J. Kovacs, “Advanced Age Impairs Macrophage Polarization,” Journal of Interferon & Cytokine Research: the Official Journal of the International Society for Interferon and Cytokine Research 32, no. 1 (2012): 18–26.

[80] H. M. Shehata, K. Hoebe, and C. A. Chougnet, “The Aged Nonhematopoietic Environment Impairs Natural Killer Cell Maturation and Function,” Aging Cell 14, no. 2 (2015): 191–199.

[81] T. Van Nguyen, N. Puebla-Osorio, H. Pang, M. E. Dujka, and C. Zhu, “DNA Damage-induced Cellular Senescence Is Sufficient to Suppress Tumorigenesis: A Mouse Model,” The Journal of Experimental Medicine 204, no. 6 (2007): 1453–1461.

[82] L. Duong, F. J. Pixley, D. J. Nelson, and C. Jackaman, “Aging Leads to Increased Monocytes and Macrophages with Altered CSF-1 Receptor Expression and Earlier Tumor-Associated Macrophage Expansion in Murine Mesothelioma,” Frontiers in Aging 3 (2022): 848925.

[83] O. Gomes Mde, M. C. Beraldo, T. C. Putarov, et al., “Old Beagle Dogs Have Lower Faecal Concentrations of some Fermentation Products and Lower Peripheral Lymphocyte Counts Than Young Adult Beagles,” British Journal of Nutrition 106, no. Suppl 1 (2011): S187–S190.

[84] A. Yamauchi, S. Yoshimoto, A. Kudo, and S. Takagi, “Negative Influence of Aging on Differentiation and Proliferation of CD8(+) T-Cells in Dogs,” Veterinary Sciences 10, no. 9 (2023): 541.

[85] A. C. Y. Chen, S. Jaiswal, D. Martinez, et al., “The Aged Tumor Microenvironment Limits T Cell Control of Cancer,” Nature Immunology 25, no. 6 (2024): 1033–1045.

[86] X. Liu, L. Li, F. Si, et al., “NK and NKT Cells Have Distinct Properties and Functions in Cancer,” Oncogene 40, no. 27 (2021): 4521–4537.

[87] C. L. Montes, A. I. Chapoval, J. Nelson, et al., “Tumor-induced Senescent T Cells With Suppressor Function: A Potential Form of Tumor Immune Evasion,” Cancer Research 68, no. 3 (2008): 870–879.

[88] S. S. Drake, A. Zaman, C. Gianfelice, et al., “Senolytic Treatment Diminishes Microglia and Decreases Severity of Experimental Autoimmune Encephalomyelitis,” Journal of Neuroinflammation 21, no. 1 (2024): 283.

[89] Z. Liang, X. Dong, Z. Zhang, Q. Zhang, and Y. Zhao, “Age-related Thymic Involution: Mechanisms and Functional Impact,” Aging Cell 21, no. 8 (2022): e13671.

[90] B. Dykstra, S. Olthof, J. Schreuder, M. Ritsema, and G. de Haan, “Clonal Analysis Reveals Multiple Functional Defects of Aged Murine Hematopoietic Stem Cells,” Journal of Experimental Medicine 208, no. 13 (2011): 2691–2703.

[91] C. A. Mitchell, E. V. Verovskaya, F. J. Calero-Nieto, et al., “Stromal Niche Inflammation Mediated by IL-1 Signalling Is a Targetable Driver of Haematopoietic Ageing,” Nature Cell Biology 25, no. 1 (2023): 30–41.

[92] D. Toghani, S. Gupte, S. Zeng, et al., “Niche-derived Semaphorin 4A Safeguards Functional Identity of Myeloid-biased Hematopoietic Stem Cells,” Nature Aging 5, no. 4 (2025): 558–575.

[93] M. T. Bocker, I. Hellwig, A. Breiling, V. Eckstein, A. D. Ho, and F. Lyko, “Genome-wide Promoter DNA Methylation Dynamics of human Hematopoietic Progenitor Cells During Differentiation and Aging,” Blood 117, no. 19 (2011): e182–e189.

[94] D. Saul and R. L. Kosinsky, “Epigenetics of Aging and Aging-Associated Diseases,” International Journal of Molecular Sciences 22, no. 1 (2021): 401.

[95] T. Y. Su, J. Hauenstein, E. Somuncular, et al., “Aging Is Associated With Functional and Molecular Changes in Distinct Hematopoietic Stem Cell Subsets,” Nature Communications 15, no. 1 (2024): 7966.

[96] R. Yamamoto, Y. Morita, J. Ooehara, et al., “Clonal Analysis Unveils Self-renewing Lineage-restricted Progenitors Generated Directly From Hematopoietic Stem Cells,” Cell 154, no. 5 (2013): 1112–1126.

[97] E. J. Yager, M. Ahmed, K. Lanzer, T. D. Randall, D. L. Woodland, and M. A. Blackman, “Age-associated Decline in T Cell Repertoire Diversity Leads to Holes in the Repertoire and Impaired Immunity to Influenza Virus,” Journal of Experimental Medicine 205, no. 3 (2008): 711–723.

[98] L. Cicin-Sain, S. Smyk-Pearson, N. Currier, et al., “Loss of Naive T Cells and Repertoire Constriction Predict Poor Response to Vaccination in Old Primates,” Journal of Immunology 184, no. 12 (2010): 6739–6745.

[99] X. Ren, Y. Wang, and Y. Zhang, “Targeted Depletion of Dysfunctional Hematopoietic Stem Cells Mitigates Myeloid-biased Differentiation in Aged Mice,” Cell Discovery 11, no. 1 (2025): 56.

[100] M. De Cecco, T. Ito, A. P. Petrashen, et al., “L1 drives IFN in Senescent Cells and Promotes Age-associated Inflammation,” Nature 566, no. 7742 (2019): 73–78.

[101] C. Liang, Q. Ke, Z. Liu, et al., “BMAL1 moonlighting as a Gatekeeper for LINE1 Repression and Cellular Senescence in Primates,” Nucleic Acids Research 50, no. 6 (2022): 3323–3347.

[102] M. M. Parisi, L. K. Grun, P. Lavandoski, et al., “Immunosenescence Induced by Plasma From Individuals With Obesity Caused Cell Signaling Dysfunction and Inflammation,” Obesity (Silver Spring) 25, no. 9 (2017): 1523–1531.

[103] M. Rivas, G. Gupta, L. Costanzo, H. Ahmed, A. E. Wyman, and P. Geraghty, “Senescence: Pathogenic Driver in Chronic Obstructive Pulmonary Disease,” Medicina (Kaunas, Lithuania) 58, no. 6 (2022): 817.

[104] I. Montali, C. Ceccatelli Berti, M. Morselli, et al., “Deregulated Intracellular Pathways Define Novel Molecular Targets for HBV-specific CD8 T Cell Reconstitution in Chronic hepatitis B,” Journal of Hepatology 79, no. 1 (2023): 50–60.

[105] P. Fisicaro, V. Barili, B. Montanini, et al., “Targeting Mitochondrial Dysfunction Can Restore Antiviral Activity of Exhausted HBV-specific CD8 T Cells in Chronic hepatitis B,” Nature Medicine 23, no. 3 (2017): 327–336.

[106] S. De Biasi, M. Meschiari, L. Gibellini, et al., “Marked T Cell Activation, Senescence, Exhaustion and Skewing towards TH17 in Patients With COVID-19 Pneumonia,” Nature Communications 11, no. 1 (2020): 3434.

[107] S. Rao, K. Gharib, and A. Han, “Cancer Immunosurveillance by T Cells,” International Review of Cell and Molecular Biology 342 (2019): 149–173.

[108] C. Laheurte, M. Dosset, D. Vernerey, et al., “Distinct Prognostic Value of Circulating Anti-telomerase CD4(+) Th1 Immunity and Exhausted PD-1(+)/TIM-3(+) T Cells in Lung Cancer,” British Journal of Cancer 121, no. 5 (2019): 405–416.

[109] P. Bule, S. I. Aguiar, F. Aires-Da-Silva, and J. N. R. Dias, “Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy,” International Journal of Molecular Sciences 22, no. 18 (2021): 9804.

[110] Z. Deng, T. Fan, and C. Xiao, “TGF-beta Signaling in Health, Disease, and Therapeutics,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 61.

[111] V. Janelle, M. Neault, M. E. Lebel, et al., “p16(INK4a) Regulates Cellular Senescence in PD-1-Expressing Human T Cells,” Frontiers in Immunology 12 (2021): 698565.

[112] G. M. Suarez, A. L. Ane-Kouri, A. Gonzalez, et al., “Associations Among Cytokines, EGF and Lymphocyte Subpopulations in Patients Diagnosed With Advanced Lung Cancer,” Cancer Immunology, Immunotherapy 70, no. 6 (2021): 1735–1743.

[113] Y. Liu, N. Zhou, L. Zhou, et al., “IL-2 Regulates Tumor-reactive CD8(+) T Cell Exhaustion by Activating the Aryl Hydrocarbon Receptor,” Nature Immunology 22, no. 3 (2021): 358–369.

[114] I. Elia, J. H. Rowe, S. Johnson, et al., “Tumor Cells Dictate Anti-tumor Immune Responses by Altering Pyruvate Utilization and Succinate Signaling in CD8(+) T Cells,” Cell Metabolism 34, no. 8 (2022): 1137–1150. e6.

[115] S. M. Henson, R. Macaulay, N. E. Riddell, C. J. Nunn, and A. N. Akbar, “Blockade of PD-1 or p38 MAP Kinase Signaling Enhances Senescent human CD8(+) T-cell Proliferation by Distinct Pathways,” European Journal of Immunology 45, no. 5 (2015): 1441–1451.

[116] Y. Liu, X. Guo, L. Zhan, L. Wang, X. Wang, and M. Jiang, “LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients,” Computational and Mathematical Methods in Medicine 2021 (2021): 4468140.

[117] M. Shahbazi, Z. Moulana, M. Sepidarkish, et al., “Pronounce Expression of Tim-3 and CD39 but Not PD1 Defines CD8 T Cells in Critical Covid-19 Patients,” Microbial Pathogenesis 153 (2021): 104779.

[118] C. L. Shive, B. Clagett, M. R. McCausland, et al., “Inflammation Perturbs the IL-7 Axis, Promoting Senescence and Exhaustion That Broadly Characterize Immune Failure in Treated HIV Infection,” Journal of Acquired Immune Deficiency Syndromes 71, no. 5 (2016): 483–492.

[119] X. Li, C. Li, W. Zhang, Y. Wang, P. Qian, and H. Huang, “Inflammation and Aging: Signaling Pathways and Intervention Therapies,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 239.

[120] H. Zhao, L. Wu, G. Yan, et al., “Inflammation and Tumor Progression: Signaling Pathways and Targeted Intervention,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 263.

[121] G. Desdín-Micó, G. Soto-Heredero, J. F. Aranda, et al., “T Cells With Dysfunctional Mitochondria Induce Multimorbidity and Premature Senescence,” Science 368, no. 6497 (2020): 1371–1376.

[122] Z. Peng, C. Liu, A. R. Victor, et al., “Tumors Exploit CXCR4(hi)CD62L(lo) Aged Neutrophils to Facilitate Metastatic Spread,” Oncoimmunology 10, no. 1 (2021): 1870811.

[123] A. Salminen, “The Role of the Immunosuppressive PD-1/PD-L1 Checkpoint Pathway in the Aging Process and Age-related Diseases,” Journal of Molecular Medicine (Berlin) 102, no. 6 (2024): 733–750.

[124] C. López-Otín, F. Pietrocola, D. Roiz-Valle, L. Galluzzi, and G. Kroemer, “Meta-hallmarks of Aging and Cancer,” Cell Metabolism 35, no. 1 (2023): 12–35.

[125] Y. Xu, C. He, Y. Xi, Y. Zhang, and Y. Bai, “Gut Microbiota and Immunosenescence in Cancer,” Seminars in Cancer Biology 104-105 (2024): 32–45.

[126] H. Nishikawa and S. Koyama, “Mechanisms of Regulatory T Cell Infiltration in Tumors: Implications for Innovative Immune Precision Therapies,” Journal for ImmunoTherapy of Cancer 9, no. 7 (2021): e002591.

[127] F. Veglia, E. Sanseviero, and D. I. Gabrilovich, “Myeloid-derived Suppressor Cells in the Era of Increasing Myeloid Cell Diversity,” Nature Reviews Immunology 21, no. 8 (2021): 485–498.

[128] T. J. Curiel, G. Coukos, L. Zou, et al., “Specific Recruitment of Regulatory T Cells in Ovarian Carcinoma Fosters Immune Privilege and Predicts Reduced Survival,” Nature Medicine 10, no. 9 (2004): 942–949.

[129] X. Liu, F. Si, D. Bagley, et al., “Blockades of Effector T Cell Senescence and Exhaustion Synergistically Enhance Antitumor Immunity and Immunotherapy,” Journal for Immunotherapy of Cancer 10, no. 10 (2022): e005020.

[130] C. Menetrier-Caux, J. Faget, C. Biota, M. Gobert, J. Y. Blay, and C. Caux, “Innate Immune Recognition of Breast Tumor Cells Mediates CCL22 Secretion Favoring Treg Recruitment Within Tumor Environment,” Oncoimmunology 1, no. 5 (2012): 759–761.

[131] F. Si, X. Liu, Y. Tao, et al., “Blocking Senescence and Tolerogenic Function of Dendritic Cells Induced by Γδ Treg Cells Enhances Tumor-specific Immunity for Cancer Immunotherapy,” Journal for ImmunoTherapy of Cancer 12, no. 4 (2024): e008219.

[132] X. Liu, W. Mo, J. Ye, et al., “Regulatory T Cells Trigger Effector T Cell DNA Damage and Senescence Caused by Metabolic Competition,” Nature Communications 9, no. 1 (2018): 249.

[133] N. Nagarsheth, M. S. Wicha, and W. Zou, “Chemokines in the Cancer Microenvironment and Their Relevance in Cancer Immunotherapy,” Nature Reviews Immunology 17, no. 9 (2017): 559–572.

[134] T. Kitamura, B. Z. Qian, D. Soong, et al., “CCL2-induced Chemokine Cascade Promotes Breast Cancer Metastasis by Enhancing Retention of Metastasis-associated Macrophages,” Journal of Experimental Medicine 212, no. 7 (2015): 1043–1059.

[135] H. Liu, Q. Zhao, L. Tan, et al., “Neutralizing IL-8 Potentiates Immune Checkpoint Blockade Efficacy for Glioma,” Cancer Cell 41, no. 4 (2023): 693–710. e8.

[136] R. Sun, Y. Xiong, H. Liu, et al., “Tumor-associated Neutrophils Suppress Antitumor Immunity of NK Cells Through the PD-L1/PD-1 Axis,” Translational Oncology 13, no. 10 (2020): 100825.

[137] H. Li, Y. Han, Q. Guo, M. Zhang, and X. Cao, “Cancer-expanded Myeloid-derived Suppressor Cells Induce Anergy of NK Cells Through Membrane-bound TGF-beta 1,” Journal of Immunology 182, no. 1 (2009): 240–249.

[138] S. M. Fendt, “100 years of the Warburg Effect: A Cancer Metabolism Endeavor,” Cell 187, no. 15 (2024): 3824–3828.

[139] X. Liu, Y. Zhao, X. Wu, Z. Liu, and X. Liu, “A Novel Strategy to Fuel Cancer Immunotherapy: Targeting Glucose Metabolism to Remodel the Tumor Microenvironment,” Frontiers in Oncology 12 (2022): 931104.

[140] J. E. Bader, K. Voss, and J. C. Rathmell, “Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy,” Molecular Cell 78, no. 6 (2020): 1019–1033.

[141] M. Jarosz-Biej, R. Smolarczyk, T. Cichoń, and N. Kułach, “Tumor Microenvironment as a "Game Changer" in Cancer Radiotherapy,” International Journal of Molecular Sciences 20, no. 13 (2019): 3212.

[142] J. Chen, Z. Huang, Y. Chen, et al., “Lactate and Lactylation in Cancer,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 38.

[143] L. Chen, L. Huang, Y. Gu, W. Cang, P. Sun, and Y. Xiang, “Lactate-Lactylation Hands Between Metabolic Reprogramming and Immunosuppression,” International Journal of Molecular Sciences 23, no. 19 (2022): 11943.

[144] A. N. Mendler, B. Hu, P. U. Prinz, M. Kreutz, E. Gottfried, and E. Noessner, “Tumor Lactic Acidosis Suppresses CTL Function by Inhibition of p38 and JNK/c-Jun Activation,” International Journal of Cancer 131, no. 3 (2012): 633–640.

[145] J. Ye, C. Ma, E. C. Hsueh, et al., “TLR8 signaling Enhances Tumor Immunity by Preventing Tumor-induced T-cell Senescence,” EMBO Molecular Medicine 6, no. 10 (2014): 1294–1311.

[146] A. Brand, K. Singer, G. E. Koehl, et al., “LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells,” Cell Metabolism 24, no. 5 (2016): 657–671.

[147] C. Harmon, M. W. Robinson, F. Hand, et al., “Lactate-Mediated Acidification of Tumor Microenvironment Induces Apoptosis of Liver-Resident NK Cells in Colorectal Liver Metastasis,” Cancer Immunology Research 7, no. 2 (2019): 335–346.

[148] M. Romero, K. Miller, A. Gelsomini, et al., “Immunometabolic Effects of Lactate on Humoral Immunity in Healthy Individuals of Different Ages,” Nature Communications 15, no. 1 (2024): 7515.

[149] D. Darshan and G. J. Anderson, “Interacting Signals in the Control of Hepcidin Expression,” Biometals 22, no. 1 (2009): 77–87.

[150] E. Joshi, M. Pandya, and U. Desai, “Current Drugs and Their Therapeutic Targets for Hypoxia-inducible Factors in Cancer,” Current Protein & Peptide Science 24, no. 6 (2023): 447–464.

[151] Y. Chen, M. Zhang, Y. He, et al., “Canadine Platinum(IV) Complexes Targeting Epithelial-Mesenchymal Transition as Antiproliferative and Antimetastatic Agents,” Journal of Medicinal Chemistry 67, no. 15 (2024): 12868–12886.

[152] M. S. Bitar, “Diabetes Impairs Angiogenesis and Induces Endothelial Cell Senescence by Up-Regulating Thrombospondin-CD47-Dependent Signaling,” International Journal of Molecular Sciences 20, no. 3 (2019): 673.

[153] J. Birch, P. J. Barnes, and J. F. Passos, “Mitochondria, Telomeres and Cell Senescence: Implications for Lung Ageing and Disease,” Pharmacology & Therapeutics 183 (2018): 34–49.

[154] H. Gao, E. Nepovimova, Z. Heger, et al., “Role of Hypoxia in Cellular Senescence,” Pharmacological Research 194 (2023): 106841.

[155] R. Kumari and P. Jat, “Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype,” Frontiers in Cell and Developmental Biology 9 (2021): 645593.

[156] Y. Wang, L. Wang, X. Wen, et al., “NF-kappaB Signaling in Skin Aging,” Mechanisms of Ageing and Development 184 (2019): 111160.

[157] Z. Guo, G. Wang, B. Wu, et al., “DCAF1 regulates Treg Senescence via the ROS Axis During Immunological Aging,” Journal of Clinical Investigation 130, no. 11 (2020): 5893–5908.

[158] D. J. Panyard, B. Yu, and M. P. Snyder, “The Metabolomics of human Aging: Advances, Challenges, and Opportunities,” Science Advances 8, no. 42 (2022): eadd6155.

[159] M. Liao, D. Yao, L. Wu, et al., “Targeting the Warburg Effect: A Revisited Perspective From Molecular Mechanisms to Traditional and Innovative Therapeutic Strategies in Cancer,” Acta Pharmaceutica Sinica B 14, no. 3 (2024): 953–1008.

[160] J. Zhang, S. Wang, X. Guo, et al., “Arginine Supplementation Targeting Tumor-Killing Immune Cells Reconstructs the Tumor Microenvironment and Enhances the Antitumor Immune Response,” ACS Nano 16, no. 8 (2022): 12964–12978.

[161] Y. Zhao, Q. Shao, and G. Peng, “Exhaustion and Senescence: Two Crucial Dysfunctional States of T Cells in the Tumor Microenvironment,” Cellular & Molecular Immunology 17, no. 1 (2020): 27–35.

[162] W. He, H. Zhang, F. Han, et al., “CD155T/TIGIT Signaling Regulates CD8(+) T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer,” Cancer Research 77, no. 22 (2017): 6375–6388.

[163] A. Lanna, D. C. Gomes, B. Muller-Durovic, et al., “A Sestrin-dependent Erk-Jnk-p38 MAPK Activation Complex Inhibits Immunity During Aging,” Nature Immunology 18, no. 3 (2017): 354–363.

[164] M. Song, T. A. Sandoval, C. S. Chae, et al., “IRE1alpha-XBP1 controls T Cell Function in Ovarian Cancer by Regulating Mitochondrial Activity,” Nature 562, no. 7727 (2018): 423–428.

[165] C. M. Cham, G. Driessens, J. P. O'Keefe, and T. F. Gajewski, “Glucose Deprivation Inhibits Multiple Key Gene Expression Events and Effector Functions in CD8+ T Cells,” European Journal of Immunology 38, no. 9 (2008): 2438–2450.

[166] M. Sukumar, J. Liu, Y. Ji, et al., “Inhibiting Glycolytic Metabolism Enhances CD8+ T Cell Memory and Antitumor Function,” Journal of Clinical Investigation 123, no. 10 (2013): 4479–4488.

[167] Z. Y. Liu, C. Y. Wu, R. Q. Wu, et al., “Efflux of N1-acetylspermidine From Hepatoma Fosters Macrophage-mediated Immune Suppression to Dampen Immunotherapeutic Efficacy,” Immunity 58, no. 6 (2025): 1572–1585.

[168] N. Ron-Harel, D. Santos, and J. M. Ghergurovich, “Mitochondrial Biogenesis and Proteome Remodeling Promote One-Carbon Metabolism for T Cell Activation,” Cell Metabolism 24, no. 1 (2016): 104–117.

[169] N. Ron-Harel, G. Notarangelo, and J. M. Ghergurovich, “Defective Respiration and One-carbon Metabolism Contribute to Impaired Naïve T Cell Activation in Aged Mice,” PNAS 115, no. 52 (2018): 13347–13352.

[170] Q. Liu, F. Zhu, X. Liu, et al., “Non-oxidative Pentose Phosphate Pathway Controls Regulatory T Cell Function by Integrating Metabolism and Epigenetics,” Nature Metabolism 4, no. 5 (2022): 559–574.

[171] S. Pinho and P. S. Frenette, “Haematopoietic Stem Cell Activity and Interactions With the Niche,” Nature Reviews Molecular Cell Biology 20, no. 5 (2019): 303–320.

[172] J. Ji, K. Ding, B. Cheng, et al., “Radiotherapy-Induced Astrocyte Senescence Promotes an Immunosuppressive Microenvironment in Glioblastoma to Facilitate Tumor Regrowth,” Advanced science (Weinheim) 11, no. 15 (2024): e2304609.

[173] L. Wang, L. Lankhorst, and R. Bernards, “Exploiting Senescence for the Treatment of Cancer,” Nature Reviews Cancer 22, no. 6 (2022): 340–355.

[174] P. Li, M. Hou, F. Lou, M. Bjorkholm, and D. Xu, “Telomere Dysfunction Induced by Chemotherapeutic Agents and Radiation in Normal human Cells,” International Journal of Biochemistry & Cell Biology 44, no. 9 (2012): 1531–1540.

[175] V. A. Alamino, L. I. Onofrio, C. D. V. Acosta, et al., “Tofacitinib Treatment of Rheumatoid Arthritis Increases Senescent T Cell Frequency in Patients and Limits T Cell Function in Vitro,” European Journal of Immunology 53, no. 8 (2023): e2250353.

[176] T. M. Rickabaugh, R. M. Baxter, M. Sehl, et al., “Acceleration of Age-associated Methylation Patterns in HIV-1-infected Adults,” PLoS ONE 10, no. 3 (2015): e0119201.

[177] X. Liu, Y. Feng, G. Xu, et al., “MAPK-Targeted Drug Delivered by a pH-Sensitive MSNP Nanocarrier Synergizes With PD-1 Blockade in Melanoma Without T-Cell Suppression,” Advanced Functional Materials 29, no. 12 (2019): 1806916.

[178] X. Wang, J. Yu, X. Liu, et al., “PSMG2-controlled Proteasome-autophagy Balance Mediates the Tolerance for MEK-targeted Therapy in Triple-negative Breast Cancer,” Cell Reports Medicine 3, no. 9 (2022): 100741.

[179] C. L. Carbonneau, G. Despars, S. Rojas-Sutterlin, et al., “Ionizing Radiation-induced Expression of INK4a/ARF in Murine Bone Marrow-derived Stromal Cell Populations Interferes With Bone Marrow Homeostasis,” Blood 119, no. 3 (2012): 717–726.

[180] J. Qian, X. Zhou, K. Tanaka, and A. Takahashi, “Alteration in the Chromatin Landscape During the DNA Damage Response: Continuous Rotation of the Gear Driving Cellular Senescence and Aging,” Dna Repair 131 (2023): 103572.

[181] R. Bogeska, A. M. Mikecin, P. Kaschutnig, et al., “Inflammatory Exposure Drives Long-lived Impairment of Hematopoietic Stem Cell Self-renewal Activity and Accelerated Aging,” Cell Stem Cell 29, no. 8 (2022): 1273–1284. e8.

[182] Y. Guan, Q. Yao, Y. Hao, et al., “The Combination of Etoposide and Platinum for the Treatment of Thymic Neuroendocrine Neoplasms: A Retrospective Analysis,” Cancer Medicine 12, no. 15 (2023): 16011–16018.

[183] Q. Li, Y. H. Zhao, C. Xu, et al., “Chemotherapy-Induced Senescence Reprogramming Promotes Nasopharyngeal Carcinoma Metastasis by circRNA-Mediated PKR Activation,” Advanced Science (Weinheim) 10, no. 8 (2023): e2205668.

[184] Y. Wang, Y. Zhao, and Z. Li, “2D Covalent Organic Frameworks as Photocatalysts for Solar Energy Utilization,” Macromolecular Rapid Communications 43, no. 16 (2022): e2200108.

[185] M. Salines, M. Andraud, M. Pellerin, et al., “Impact of Porcine Circovirus Type 2 (PCV2) Infection on hepatitis E Virus (HEV) Infection and Transmission Under Experimental Conditions,” Veterinary Microbiology 234 (2019): 1–7.

[186] M. Le Garff-Tavernier, V. Beziat, and J. Decocq, “Human NK Cells Display Major Phenotypic and Functional Changes Over the Life Span,” Aging Cell 9, no. 4 (2010): 527–535.

[187] J. Hazeldine, P. Hampson, and J. M. Lord, “Reduced Release and Binding of Perforin at the Immunological Synapse Underlies the Age-related Decline in Natural Killer Cell Cytotoxicity,” Aging Cell 11, no. 5 (2012): 751–779.

[188] E. Good, L. Åkerman, S. Nyström, L. Jonasson, J. Ernerudh, and E. de Muinck, “Changes in Natural Killer and T Lymphocyte Phenotypes in Response to Cardiovascular Risk Management,” Scientific Reports 13, no. 1 (2023): 20810.

[189] S. Lopez-Vergès, J. M. Milush, B. S. Schwartz, et al., “Expansion of a Unique CD57⁺NKG2Chi Natural Killer Cell Subset During Acute human cytomegalovirus Infection,” PNAS 108, no. 36 (2011): 14725–14732.

[190] C. Qi and Q. Liu, “Natural Killer Cells in Aging and Age-related Diseases,” Neurobiology of Disease 183 (2023): 106156.

[191] Y. Lu, K. Li, Y. Hu, and X. Wang, “Expression of Immune Related Genes and Possible Regulatory Mechanisms in Alzheimer's Disease,” Frontiers in immunology 12 (2021): 768966.

[192] R. Krishnaraj, “Senescence and Cytokines Modulate the NK Cell Expression,” Mechanisms of Ageing and Development 96, no. 1-3 (1997): 89–101.

[193] D. Rukavina, G. Laskarin, G. Rubesa, et al., “Age-related Decline of Perforin Expression in human Cytotoxic T Lymphocytes and Natural Killer Cells,” Blood 92, no. 7 (1998): 2410–2420.

[194] D. D. Billadeau, J. L. Upshaw, R. A. Schoon, C. J. Dick, and P. J. Leibson, “NKG2D-DAP10 triggers human NK Cell-mediated Killing via a Syk-independent Regulatory Pathway,” Nature Immunology 4, no. 6 (2003): 557–564.

[195] C. Fauriat, S. Just-Landi, F. Mallet, et al., “Deficient Expression of NCR in NK Cells From Acute Myeloid Leukemia: Evolution During Leukemia Treatment and Impact of Leukemia Cells in NCRdull Phenotype Induction,” Blood 109, no. 1 (2007): 323–330.

[196] B. Sanchez-Correa, S. Morgado, I. Gayoso, et al., “Human NK Cells in Acute Myeloid Leukaemia Patients: Analysis of NK Cell-activating Receptors and Their Ligands,” Cancer Immunology, Immunotherapy 60, no. 8 (2011): 1195–1205.

[197] A. Y. Mah and M. A. Cooper, “Metabolic Regulation of Natural Killer Cell IFN-γ Production,” Critical Reviews in Immunology 36, no. 2 (2016): 131–147.

[198] A. Y. Mah, A. Rashidi, M. P. Keppel, et al., “Glycolytic Requirement for NK Cell Cytotoxicity and cytomegalovirus Control,” JCI Insight 2, no. 23 (2017): e95128.

[199] C. Jackaman, D. E. Dye, and D. J. Nelson, “IL-2/CD40-activated Macrophages Rescue Age and Tumor-induced T Cell Dysfunction in Elderly Mice,” Age (Dordrecht, Netherlands) 36, no. 3 (2014): 9655.

[200] Y. Wang, M. Wehling-Henricks, G. Samengo, and J. G. Tidball, “Increases of M2a Macrophages and Fibrosis in Aging Muscle Are Influenced by Bone Marrow Aging and Negatively Regulated by Muscle-derived Nitric Oxide,” Aging Cell 14, no. 4 (2015): 678–688.

[201] L. Fontana, E. Zhao, M. Amir, H. Dong, K. Tanaka, and M. J. Czaja, “Aging Promotes the Development of Diet-induced Murine Steatohepatitis but Not Steatosis,” Hepatology (Baltimore, Md) 57, no. 3 (2013): 995–1004.

[202] C. N. Lumeng, J. Liu, L. Geletka, et al., “Aging Is Associated With an Increase in T Cells and Inflammatory Macrophages in Visceral Adipose Tissue,” Journal of Immunology (Baltimore, Md: 1950) 187, no. 12 (2011): 6208–6216.

[203] L. Ayerra and M. S. Aymerich, “Complementary Roles of Glial Cells in Generating Region-specific Neuroinflammatory Responses and Phagocytosis in Parkinson's disease,” Neural Regen Res 20, no. 10 (2025): 2917–2918.

[204] W. Xiang, T. Zhang, B. Li, et al., “Senescent Macrophages Induce Ferroptosis in Skeletal Muscle and Accelerate Osteoarthritis-related Muscle Atrophy,” Nature Aging 5, no. 7 (2025): 1295–1316.

[205] B. M. Hall, V. Balan, A. S. Gleiberman, et al., “Aging of Mice Is Associated With p16(Ink4a)- and β-galactosidase-positive Macrophage Accumulation That Can be Induced in Young Mice by Senescent Cells,” Aging 8, no. 7 (2016): 1294–1315.

[206] R. Noy and J. W. Pollard, “Tumor-associated Macrophages: From Mechanisms to Therapy,” Immunity 41, no. 1 (2014): 49–61.

[207] P. Sinha, V. K. Clements, S. Miller, and S. Ostrand-Rosenberg, “Tumor Immunity: A Balancing Act Between T Cell Activation, Macrophage Activation and Tumor-induced Immune Suppression,” Cancer Immunology, Immunotherapy: CII 54, no. 11 (2005): 1137–1142.

[208] B. Toledo, L. Zhu Chen, M. Paniagua-Sancho, J. A. Marchal, M. Perán, and E. Giovannetti, “Deciphering the Performance of Macrophages in Tumour Microenvironment: A Call for Precision Immunotherapy,” Journal of Hematology & Oncology 17, no. 1 (2024): 44.

[209] H. Wada, R. Otsuka, W. T. V. Germeraad, T. Murata, T. Kondo, and K. I. Seino, “Tumor Cell-induced Macrophage Senescence Plays a Pivotal Role in Tumor Initiation Followed by Stable Growth in Immunocompetent Condition,” Journal for ImmunoTherapy of Cancer 11, no. 11 (2023): e006677.

[210] M. Akkaya, K. Kwak, and S. K. Pierce, “B Cell Memory: Building Two Walls of Protection Against Pathogens,” Nature Reviews Immunology 20, no. 4 (2020): 229–238.

[211] R. Carsetti, C. Quintarelli, I. Quinti, et al., “The Immune System of Children: The Key to Understanding SARS-CoV-2 Susceptibility?,” Lancet Child Adolesc Health 4, no. 6 (2020): 414–416.

[212] M. Ratliff, S. Alter, D. Frasca, B. B. Blomberg, and R. L. Riley, “In Senescence, Age-associated B Cells Secrete TNFα and Inhibit Survival of B-cell Precursors,” Aging Cell 12, no. 2 (2013): 303–311.

[213] F. Ma, Y. Cao, H. Du, et al., “Three-dimensional Chromatin Reorganization Regulates B Cell Development During Ageing,” Nature Cell Biology 26, no. 6 (2024): 991–1002.

[214] M. Bulati, C. Caruso, and G. Colonna-Romano, “From Lymphopoiesis to Plasma Cells Differentiation, the Age-related Modifications of B Cell Compartment Are Influenced by "Inflamm-ageing",” Ageing Research Reviews 36 (2017): 125–136.

[215] M. Ciocca, S. Zaffina, A. Fernandez Salinas, et al., “Evolution of Human Memory B Cells from Childhood to Old Age,” Frontiers in immunology 12 (2021): 690534.

[216] S. Palmer, L. Albergante, C. C. Blackburn, and T. J. Newman, “Thymic Involution and Rising Disease Incidence With Age,” PNAS 115, no. 8 (2018): 1883–1888.

[217] S. Kawamoto, K. Uemura, N. Hori, et al., “Bacterial Induction of B Cell Senescence Promotes Age-related Changes in the Gut Microbiota,” Nature Cell Biology 25, no. 6 (2023): 865–876.

[218] D. Frasca and B. B. Blomberg, “Inflammaging Decreases Adaptive and Innate Immune Responses in Mice and Humans,” Biogerontology 17, no. 1 (2016): 7–19.

[219] D. Frasca, R. L. Riley, and B. B. Blomberg, “Humoral Immune Response and B-cell Functions Including Immunoglobulin Class Switch Are Downregulated in Aged Mice and Humans,” Seminars in Immunology 17, no. 5 (2005): 378–384.

[220] G. Xie, X. Chen, Y. Gao, et al., “Age-Associated B Cells in Autoimmune Diseases: Pathogenesis and Clinical Implications,” Clinical Reviews in Allergy & Immunology 68, no. 1 (2025): 18.

[221] L. L. Xiong, L. L. Xue, R. L. Du, et al., “Single-cell RNA Sequencing Reveals B Cell-related Molecular Biomarkers for Alzheimer's Disease,” Experimental & Molecular Medicine 53, no. 12 (2021): 1888–1901.

[222] S. Rinaldi, S. Pallikkuth, V. K. George, et al., “Paradoxical Aging in HIV: Immune Senescence of B Cells Is Most Prominent in Young Age,” Aging (Albany NY) 9, no. 4 (2017): 1307–1325.

[223] X. Hao, Y. Shen, J. Liu, et al., “Solid Tumour-induced Systemic Immunosuppression Involves Dichotomous Myeloid-B Cell Interactions,” Nature Cell Biology 26, no. 11 (2024): 1971–1983.

[224] S. Garaud, L. Buisseret, C. Solinas, et al., “Tumor Infiltrating B-cells Signal Functional Humoral Immune Responses in Breast Cancer,” JCI Insight 5, no. 18 (2019): e129641.

[225] J. Chen, Y. Tan, F. Sun, et al., “Single-cell Transcriptome and Antigen-immunoglobin Analysis Reveals the Diversity of B Cells in Non-small Cell Lung Cancer,” Genome Biology 21, no. 1 (2020): 152.

[226] A. Montfort, O. Pearce, E. Maniati, et al., “A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases,” Clinical Cancer Research 23, no. 1 (2017): 250–262.

[227] K. T. Lynch, S. J. Young, M. O. Meneveau, et al., “Heterogeneity in Tertiary Lymphoid Structure B-cells Correlates With Patient Survival in Metastatic Melanoma,” Journal for ImmunoTherapy of Cancer 9, no. 6 (2021): e002273.

[228] J. Gunderson A, V. Rajamanickam, C. Bui, et al., “Germinal Center Reactions in Tertiary Lymphoid Structures Associate With Neoantigen Burden, Humoral Immunity and Long-term Survivorship in Pancreatic Cancer,” Oncoimmunology 10, no. 1 (2021): 1900635.

[229] A. M. Wertheimer, M. S. Bennett, B. Park, et al., “Aging and cytomegalovirus Infection Differentially and Jointly Affect Distinct Circulating T Cell Subsets in Humans,” Journal of Immunology 192, no. 5 (2014): 2143–2155.

[230] K. P. Burke, A. Chaudhri, G. J. Freeman, and A. H. Sharpe, “The B7:CD28 family and Friends: Unraveling Coinhibitory Interactions,” Immunity 57, no. 2 (2024): 223–244.

[231] B. Feng, Z. Bai, X. Zhou, et al., “The Type 2 Cytokine Fc-IL-4 Revitalizes Exhausted CD8(+) T Cells Against Cancer,” Nature 634, no. 8034 (2024): 712–720.

[232] K. Hebel, S. Weinert, B. Kuropka, et al., “CD4+ T Cells From human Neonates and Infants Are Poised Spontaneously to Run a Nonclassical IL-4 Program,” Journal of Immunology 192, no. 11 (2014): 5160–5170.

[233] R. Franzin, A. Stasi, G. Castellano, and L. Gesualdo, “Methods for Characterization of Senescent Circulating and Tumor-Infiltrating T-Cells: An Overview From Multicolor Flow Cytometry to Single-Cell RNA Sequencing,” Methods in Molecular Biology 2325 (2021): 79–95.

[234] M. S. Shin, H. J. Park, S. Salahuddin, et al., “Alterations in High-dimensional T-cell Profile and Gene Signature of Immune Aging in HIV-infected Older Adults Without Viremia,” Aging Cell 21, no. 10 (2022): e13702.

[235] D. Schmidt, J. J. Goronzy, and C. M. Weyand, “CD4+ CD7- CD28- T Cells Are Expanded in Rheumatoid Arthritis and Are Characterized by Autoreactivity,” Journal of Clinical Investigation 97, no. 9 (1996): 2027–2037.

[236] P. Bohacova, M. Terekhova, P. Tsurinov, et al., “Multidimensional Profiling of human T Cells Reveals High CD38 Expression, Marking Recent Thymic Emigrants and Age-related Naive T Cell Remodeling,” Immunity 57, no. 10 (2024): 2362–2379. e10.

[237] S. Shang, Y. W. Yang, F. Chen, et al., “TRIB3 reduces CD8(+) T Cell Infiltration and Induces Immune Evasion by Repressing the STAT1-CXCL10 Axis in Colorectal Cancer,” Science Translational Medicine 14, no. 626 (2022): eabf0992.

[238] M. A. Garcia-Marquez, M. Thelen, S. Reinke, et al., “Reverted Exhaustion Phenotype of Circulating Lymphocytes as Immune Correlate of Anti-PD1 First-line Treatment in Hodgkin lymphoma,” Leukemia 36, no. 3 (2022): 760–771.

[239] O. O. Onyema, L. Decoster, R. Njemini, et al., “Chemotherapy-induced Changes and Immunosenescence of CD8+ T-cells in Patients With Breast Cancer,” Anticancer Research 35, no. 3 (2015): 1481–1489.

[240] J. B. Chen, X. F. Kong, W. Qian, et al., “Two Weeks of Hydrogen Inhalation Can Significantly Reverse Adaptive and Innate Immune System Senescence Patients With Advanced Non-small Cell Lung Cancer: A Self-controlled Study,” Medical Gas Research 10, no. 4 (2020): 149–154.

[241] A. Papalampros, M. Vailas, K. Ntostoglou, et al., “Unique Spatial Immune Profiling in Pancreatic Ductal Adenocarcinoma With Enrichment of Exhausted and Senescent T Cells and Diffused CD47-SIRPα Expression,” Cancers (Basel) 12, no. 7 (2020): 1825.

[242] X. Zhao, C. Yuan, D. Wangmo, and S. Subramanian, “Tumor-Secreted Extracellular Vesicles Regulate T-Cell Costimulation and Can Be Manipulated To Induce Tumor-Specific T-Cell Responses,” Gastroenterology 161, no. 2 (2021): 560–574. e11.

[243] C. Chen, D. Chen, Y. Zhang, et al., “Changes of CD4+CD25+FOXP3+ and CD8+CD28- regulatory T Cells in Non-small Cell Lung Cancer Patients Undergoing Surgery,” International Immunopharmacology 18, no. 2 (2014): 255–261.

[244] I. Sturmlechner, A. Jain, B. Hu, et al., “Antigen Specificity Shapes Distinct Aging Trajectories of Memory CD8⁺ T Cells,” Nature Communications 16, no. 1 (2025): 6394.

[245] K. Bardhan, T. Anagnostou, and V. A. Boussiotis, “The PD1:PD-L1/2 Pathway From Discovery to Clinical Implementation,” Frontiers in Immunology 7 (2016): 550.

[246] S. P. Wu, R. Q. Liao, H. Y. Tu, et al., “Stromal PD-L1-Positive Regulatory T Cells and PD-1-Positive CD8-Positive T Cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy,” Journal of Thoracic Oncology 13, no. 4 (2018): 521–532.

[247] X. Wang, L. Lu, X. Hong, et al., “Cell-intrinsic PD-L1 Ablation Sustains Effector CD8(+) T Cell Responses and Promotes Antitumor T Cell Therapy,” Cell Reports 43, no. 2 (2024): 113712.

[248] F. Ma, X. Liu, Y. Zhang, et al., “Tumor Extracellular Vesicle-derived PD-L1 Promotes T Cell Senescence Through Lipid Metabolism Reprogramming,” Science Translational Medicine 17, no. 785 (2025): eadm7269.

[249] T. W. Wang, Y. Johmura, N. Suzuki, et al., “Blocking PD-L1-PD-1 Improves Senescence Surveillance and Ageing Phenotypes,” Nature 611, no. 7935 (2022): 358–364.

[250] N. Minato, M. Hattori, and Y. Hamazaki, “Physiology and Pathology of T-cell Aging,” International Immunology 32, no. 4 (2020): 223–231.

[251] K. J. V. Dahlquist, M. A. Huggins, M. J. Yousefzadeh, et al., “PD1 blockade Improves Survival and CD8(+) Cytotoxic Capacity, Without Increasing Inflammation, During Normal Microbial Experience in Old Mice,” Nature Aging 4, no. 7 (2024): 915–925.

[252] L. Guerra, L. Bonetti, and D. Brenner, “Metabolic Modulation of Immunity: A New Concept in Cancer Immunotherapy,” Cell Reports 32, no. 1 (2020): 107848.

[253] S. M. Henson, A. Lanna, and N. E. Riddell, “p38 signaling Inhibits mTORC1-independent Autophagy in Senescent human CD8⁺ T Cells,” The Journal of Clinical Investigation 124, no. 9 (2014): 4004–4016.

[254] Y. Yan, L. Huang, Y. Liu, et al., “Metabolic Profiles of Regulatory T Cells and Their Adaptations to the Tumor Microenvironment: Implications for Antitumor Immunity,” Journal of hematology & oncology 15, no. 1 (2022): 104.

[255] L. Li, X. Liu, K. L. Sanders, et al., “TLR8-Mediated Metabolic Control of Human Treg Function: A Mechanistic Target for Cancer Immunotherapy,” Cell metabolism 29, no. 1 (2019): 103–123. e5.

[256] M. B. Ahmed, A. A. A. Alghamdi, S. U. Islam, J. S. Lee, and Y. S. Lee, “cAMP Signaling in Cancer: A PKA-CREB and EPAC-Centric Approach,” Cells 11, no. 13 (2022): 2020.

[257] J. J. Goronzy and C. M. Weyand, “Mechanisms Underlying T Cell Ageing,” Nature Reviews Immunology 19, no. 9 (2019): 573–583.

[258] P. Gascard and T. D. Tlsty, “Carcinoma-associated Fibroblasts: Orchestrating the Composition of Malignancy,” Genes & Development 30, no. 9 (2016): 1002–1019.

[259] F. Macian, “Autophagy in T Cell Function and Aging,” Frontiers in Cell and Developmental Biology 7 (2019): 213.

[260] Z. Dong, Y. Luo, Z. Yuan, Y. Tian, T. Jin, and F. Xu, “Cellular Senescence and SASP in Tumor Progression and Therapeutic Opportunities,” Molecular Cancer 23, no. 1 (2024): 181.

[261] L. Lau, A. Porciuncula, A. Yu, Y. Iwakura, and G. David, “Uncoupling the Senescence-Associated Secretory Phenotype From Cell Cycle Exit via Interleukin-1 Inactivation Unveils Its Protumorigenic Role,” Molecular and Cellular Biology 39, no. 12 (2019): e00586.

[262] E. L. Kuan and S. F. Ziegler, “A Tumor-myeloid Cell Axis, Mediated via the Cytokines IL-1α and TSLP, Promotes the Progression of Breast Cancer,” Nature Immunology 19, no. 4 (2018): 366–374.

[263] K. Hänggi, J. Li, A. Gangadharan, et al., “Interleukin-1α Release During Necrotic-Like Cell Death Generates Myeloid-driven Immunosuppression That Restricts Anti-tumor Immunity,” Cancer Cell 42, no. 12 (2024): 2015–2031. e11.

[264] J. L. Buhl, F. Selt, T. Hielscher, et al., “The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma,” Clinical Cancer Research 25, no. 6 (2019): 1851–1866.

[265] M. Ruscetti, J. P. Morris, R. Mezzadra, et al., “Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer,” Cell 181, no. 2 (2020): 424–441. e21.

[266] N. Caronni, F. La Terza, F. M. Vittoria, et al., “IL-1β(+) Macrophages Fuel Pathogenic Inflammation in Pancreatic Cancer,” Nature 623, no. 7986 (2023): 415–422.

[267] J. X. Chen, C. S. Cheng, H. F. Gao, et al., “Overexpression of Interferon-Inducible Protein 16 Promotes Progression of Human Pancreatic Adenocarcinoma through Interleukin-1β-Induced Tumor-Associated Macrophage Infiltration in the Tumor Microenvironment,” Frontiers in Cell and Developmental Biology 9 (2021): 640786.

[268] E. Koncina, M. Nurmik, V. I. Pozdeev, et al., “IL1R1(+) cancer-associated Fibroblasts Drive Tumor Development and Immunosuppression in Colorectal cancer,” Nature Communications 14, no. 1 (2023): 4251.

[269] S. Li, C. Huang, G. Hu, et al., “Tumor-educated B Cells Promote Renal Cancer Metastasis via Inducing the IL-1β/HIF-2α/Notch1 Signals,” Cell Death & Disease 11, no. 3 (2020): 163.

[270] M. D. Wellenstein, S. B. Coffelt, D. E. M. Duits, et al., “Loss of p53 Triggers WNT-dependent Systemic Inflammation to Drive Breast Cancer Metastasis,” Nature 572, no. 7770 (2019): 538–542.

[271] S. Zhan, K. Wang, Y. Song, et al., “Long Non-coding RNA HOTAIR Modulates Intervertebral Disc Degenerative Changes via Wnt/β-catenin Pathway,” Arthritis Research & Therapy 21, no. 1 (2019): 201.

[272] Z. B. Chen, Y. B. Yu, Q. B. Wa, J. W. Zhou, M. He, and Y. Cen, “The Role of Quinazoline in Ameliorating Intervertebral Disc Degeneration by Inhibiting Oxidative Stress and Anti-inflammation via NF-κB/MAPKs Signaling Pathway,” European Review for Medical and Pharmacological Sciences 24, no. 4 (2020): 2077–2086.

[273] M. Patlán, A. Páez, F. Massó, and L. M. Amezcua-Guerra, “Relative Increase of Th17 Phenotype in Senescent CD4+CD28null T Cells From Peripheral Blood of Patients With Rheumatoid Arthritis,” Clinical and Experimental Rheumatology 39, no. 4 (2021): 925–926.

[274] B. Shen, J. Melrose, P. Ghosh, and F. Taylor, “Induction of Matrix Metalloproteinase-2 and -3 Activity in Ovine Nucleus Pulposus Cells Grown in Three-dimensional Agarose Gel Culture by Interleukin-1beta: A Potential Pathway of Disc Degeneration,” European Spine Journal 12, no. 1 (2003): 66–75.

[275] P. J. Barnes, “Inflammatory Mechanisms in Patients With Chronic Obstructive Pulmonary Disease,” Journal of Allergy and Clinical Immunology 138, no. 1 (2016): 16–27.

[276] W. Mai and Y. Liao, “Targeting IL-1β in the Treatment of Atherosclerosis,” Frontiers in Immunology 11 (2020): 589654.

[277] P. Ortiz-Montero, A. Londoño-Vallejo, and J. P. Vernot, “Senescence-associated IL-6 and IL-8 Cytokines Induce a Self- and Cross-reinforced Senescence/Inflammatory Milieu Strengthening Tumorigenic Capabilities in the MCF-7 Breast Cancer Cell Line,” Cell Communication and Signaling 15, no. 1 (2017): 17.

[278] Y. C. Yu, P. M. Yang, Q. Y. Chuah, et al., “Radiation-induced Senescence in Securin-deficient Cancer Cells Promotes Cell Invasion Involving the IL-6/STAT3 and PDGF-BB/PDGFR Pathways,” Scientific Reports 3 (2013): 1675.

[279] P. Sansone, G. Storci, S. Tavolari, et al., “IL-6 Triggers Malignant Features in Mammospheres From human Ductal Breast Carcinoma and Normal Mammary Gland,” Journal of Clinical Investigation 117, no. 12 (2007): 3988–4002.

[280] M. F. Zacarias-Fluck, B. Morancho, R. Vicario, et al., “Effect of Cellular Senescence on the Growth of HER2-positive Breast Cancers,” JNCI: Journal of the National Cancer Institute 107, no. 5 (2015): djv020.

[281] Z. C. Hartman, G. M. Poage, P. den Hollander, et al., “Growth of Triple-negative Breast Cancer Cells Relies Upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8,” Cancer Research 73, no. 11 (2013): 3470–3480.

[282] J. R. Herdy, L. Traxler, R. K. Agarwal, et al., “Increased Post-mitotic Senescence in Aged human Neurons Is a Pathological Feature of Alzheimer's disease,” Cell Stem Cell 29, no. 12 (2022): 1637–1652. e6.

[283] M. Wang, H. Zhang, J. Liang, J. Huang, and N. Chen, “Exercise Suppresses Neuroinflammation for Alleviating Alzheimer's Disease,” Journal of Neuroinflammation 20, no. 1 (2023): 76.

[284] X. Wang, L. Lin, X. Chai, Y. Wu, Y. Li, and X. Liu, “Hypoxic Mast Cells Accelerate the Proliferation, Collagen Accumulation and Phenotypic Alteration of human Lung Fibroblasts,” International Journal of Molecular Medicine 45, no. 1 (2020): 175–185.

[285] W. Gong, J. M. Hoffmann, S. Stock, et al., “Comparison of IL-2 vs IL-7/IL-15 for the Generation of NY-ESO-1-specific T Cells,” Cancer Immunology, Immunotherapy 68, no. 7 (2019): 1195–1209.

[286] D. Li, T. Liang, L. E. Hutchins, et al., “rhIL-7-hyFc, a Long-acting Interleukin-7, Improves Efficacy of CAR-T Cell Therapy in Solid Tumors,” Journal for ImmunoTherapy of Cancer 12, no. 7 (2024): e008989.

[287] A. Koyas, S. Tucer, M. Kayhan, A. C. Savas, I. Akdemir, and C. Cekic, “Interleukin-7 Protects CD8(+) T Cells From Adenosine-mediated Immunosuppression,” Science signaling 14, no. 674 (2021): eabb1269.

[288] C. Yao, Y. Lin, C. S. Ye, J. Bi, Y. F. Zhu, and S. M. Wang, “Role of Interleukin-8 in the Progression of Estrogen Receptor-negative Breast Cancer,” Chinese Medical Journal 120, no. 20 (2007): 1766–1772.

[289] Y. Lin, R. Huang, L. Chen, et al., “Identification of Interleukin-8 as Estrogen Receptor-regulated Factor Involved in Breast Cancer Invasion and Angiogenesis by Protein Arrays,” International Journal of Cancer 109, no. 4 (2004): 507–515.

[290] M. Schadendorf, W. Algermissen, and C. Sticherling, “IL-8 Produced by human Malignant Melanoma Cells in Vitro Is an Essential Autocrine Growth Factor,” Journal of Immunology 153, no. 7 (1994): 3360.

[291] Y. Huang, X. Yang, Y. Meng, et al., “The Hepatic Senescence-associated Secretory Phenotype Promotes Hepatocarcinogenesis Through Bcl3-dependent Activation of Macrophages,” Cell Bioscience 11, no. 1 (2021): 173.

[292] M. J. Del Rey, Á. Valín, A. Usategui, et al., “Senescent Synovial Fibroblasts Accumulate Prematurely in Rheumatoid Arthritis Tissues and Display an Enhanced Inflammatory Phenotype,” Immunity & Ageing 16 (2019): 29.

[293] T. Zhang, X. Liu, Y. Zhao, X. Xu, Y. Liu, and X. Wu, “Excessive IL-15 Promotes Cytotoxic CD4 + CD28- T Cell-mediated Renal Injury in Lupus Nephritis,” Immunity & Ageing 19, no. 1 (2022): 50.

[294] S. Wang, J. Wang, V. Kumar, et al., “IL-21 Drives Expansion and Plasma Cell Differentiation of Autoreactive CD11c(hi)T-bet(+) B Cells in SLE,” Nature Communications 9, no. 1 (2018): 1758.

[295] J. Augustine, S. Pavlou, I. Ali, et al., “IL-33 Deficiency Causes Persistent Inflammation and Severe Neurodegeneration in Retinal Detachment,” Journal of Neuroinflammation 16, no. 1 (2019): 251.

[296] J. P. Coppé, C. K. Patil, F. Rodier, et al., “A human-Like Senescence-associated Secretory Phenotype Is Conserved in Mouse Cells Dependent on Physiological Oxygen,” PLoS ONE 5, no. 2 (2010): e9188.

[297] J. Hu, Q. Zhao, L. Y. Kong, et al., “Regulation of Tumor Immune Suppression and Cancer Cell Survival by CXCL1/2 Elevation in Glioblastoma Multiforme,” Science Advances 7, no. 5 (2021): eabc2511.

[298] A. Bianchi, C. De I. Silva, et al., “Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer,” Cancer discovery 13, no. 6 (2023): 1428–1453.

[299] X. Xu, Z. Zhang, J. Du, et al., “Recruiting T-Cells Toward the Brain for Enhanced Glioblastoma Immunotherapeutic Efficacy by Co-Delivery of Cytokines and Immune Checkpoint Antibodies With Macrophage-Membrane-Camouflaged Nanovesicles,” Advanced Materials 35, no. 25 (2023): e2209785.

[300] X. Jie, Y. Chen, Y. Zhao, et al., “Targeting KDM4C Enhances CD8(+) T Cell Mediated Antitumor Immunity by Activating Chemokine CXCL10 Transcription in Lung Cancer,” Journal for ImmunoTherapy of Cancer 10, no. 2 (2022): e003716.

[301] L. Li, S. Hao, M. Gao, et al., “HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells,” Cancer immunology research 11, no. 5 (2023): 657–673.

[302] C. M. Cunningham, M. Li, G. Ruffenach, et al., “Y-Chromosome Gene, Uty, Protects against Pulmonary Hypertension by Reducing Proinflammatory Chemokines,” American Journal of Respiratory and Critical Care Medicine 206, no. 2 (2022): 186–196.

[303] Correction to: CCL24. CXCL9 and CXCL10 Are Increased in Synovial Fluid in Patients With Juvenile Idiopathic Arthritis Requiring Advanced Treatment. Rheumatology 2025;64(3):1535.

[304] H. J. Hwang, Y. R. Lee, D. Kang, et al., “Endothelial Cells Under Therapy-induced Senescence Secrete CXCL11, Which Increases Aggressiveness of Breast Cancer Cells,” Cancer Letters 490 (2020): 100–110.

[305] D. Di Mitri, M. Mirenda, J. Vasilevska, et al., “Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer,” Cell reports 28, no. 8 (2019): 2156–2168. e5.

[306] Y. Cao, N. Jiao, T. Sun, et al., “CXCL11 Correlates with Antitumor Immunity and an Improved Prognosis in Colon Cancer,” Frontiers in Cell and Developmental Biology 9 (2021): 646252.

[307] B. D. Lehmann, M. S. Paine, A. M. Brooks, et al., “Senescence-associated Exosome Release From human Prostate Cancer Cells,” Cancer Research 68, no. 19 (2008): 7864–7871.

[308] I. Heidegger, G. Fotakis, A. Offermann, et al., “Comprehensive Characterization of the Prostate Tumor Microenvironment Identifies CXCR4/CXCL12 Crosstalk as a Novel Antiangiogenic Therapeutic Target in Prostate Cancer,” Molecular cancer 21, no. 1 (2022): 132.

[309] D. Maggiorani, O. Le, V. Lisi, et al., “Senescence Drives Immunotherapy Resistance by Inducing an Immunosuppressive Tumor Microenvironment,” Nature Communications 15, no. 1 (2024): 2435.

[310] Y. Lu, Y. Liu, X. Zuo, et al., “CXCL12(+) tumor-associated Endothelial Cells Promote Immune Resistance in Hepatocellular Carcinoma,” Journal of Hepatology 82, no. 4 (2024): 634–648.

[311] M. M. Steele, A. Jaiswal, I. Delclaux, et al., “T Cell Egress via Lymphatic Vessels Is Tuned by Antigen Encounter and Limits Tumor Control,” Nature Immunology 24, no. 4 (2023): 664–675.

[312] R. Wei, J. Li, W. Lin, et al., “Nanoparticle-mediated Blockade of CXCL12/CXCR4 Signaling Enhances Glioblastoma Immunotherapy: Monitoring Early Responses With MRI Radiomics,” Acta Biomaterialia 177 (2024): 414–430.

[313] J. L. Pablos, B. Santiago, M. Galindo, et al., “Synoviocyte-derived CXCL12 Is Displayed on Endothelium and Induces Angiogenesis in Rheumatoid Arthritis,” Journal of Immunology 170, no. 4 (2003): 2147–2152.

[314] P. F. Bradfield, N. Amft, E. Vernon-Wilson, et al., “Rheumatoid Fibroblast-Like Synoviocytes Overexpress the Chemokine Stromal Cell-derived Factor 1 (CXCL12), Which Supports Distinct Patterns and Rates of CD4+ and CD8+ T Cell Migration Within Synovial Tissue,” Arthritis and Rheumatism 48, no. 9 (2003): 2472–2482.

[315] T. Eggert, K. Wolter, J. Ji, et al., “Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression,” Cancer Cell 30, no. 4 (2016): 533–547.

[316] S. C. Shen, J. Xu, C. Cheng, et al., “Macrophages Promote the Transition From Myocardial Ischemia Reperfusion Injury to Cardiac Fibrosis in Mice Through GMCSF/CCL2/CCR2 and Phenotype Switching,” Acta Pharmacologica Sinica 45, no. 5 (2024): 959–974.

[317] K. Eisinger, S. Bauer, A. Schäffler, et al., “Chemerin Induces CCL2 and TLR4 in Synovial Fibroblasts of Patients With Rheumatoid Arthritis and Osteoarthritis,” Experimental and Molecular Pathology 92, no. 1 (2012): 90–96.

[318] F. Tacke, D. Alvarez, T. J. Kaplan, et al., “Monocyte Subsets Differentially Employ CCR2, CCR5, and CX3CR1 to Accumulate Within Atherosclerotic Plaques,” Journal of Clinical Investigation 117, no. 1 (2007): 185–194.

[319] A. E. Vilgelm, J. S. Pawlikowski, Y. Liu, et al., “Mdm2 and Aurora Kinase a Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells,” Cancer Research 75, no. 1 (2015): 181–193.

[320] K. Wang, X. Chen, P. Lin, et al., “CD147-K148me2-Driven Tumor Cell-Macrophage Crosstalk Provokes NSCLC Immunosuppression via the CCL5/CCR5 Axis,” Advanced science (Weinheim) 11, no. 29 (2024): e2400611.

[321] C. Jacobs, S. Shah, W. C. Lu, et al., “HSF1 Inhibits Antitumor Immune Activity in Breast Cancer by Suppressing CCL5 to Block CD8+ T-cell Recruitment,” Cancer Research 84, no. 2 (2024): 276–290.

[322] P. S. Gross, V. D. Laforet, Z. Manavi, et al., “Senescent-Like Microglia Limit Remyelination Through the Senescence Associated Secretory Phenotype,” BioRxiv (2024).

[323] Y. Liu, J. Pan, X. Pan, et al., “Klotho-mediated Targeting of CCL2 Suppresses the Induction of Colorectal Cancer Progression by Stromal Cell Senescent Microenvironments,” Molecular Oncology 13, no. 11 (2019): 2460–2475.

[324] J. He, X. Chai, Q. Zhang, et al., “The Lactate Receptor HCAR1 Drives the Recruitment of Immunosuppressive PMN-MDSCs in Colorectal Cancer,” Nature Immunology 26, no. 3 (2025): 391–403.

[325] F. Moadab, H. Khorramdelazad, and M. Abbasifard, “Role of CCL2/CCR2 Axis in the Immunopathogenesis of Rheumatoid Arthritis: Latest Evidence and Therapeutic Approaches,” Life Sciences 269 (2021): 119034.

[326] F. Yang, J. A. Tuxhorn, S. J. Ressler, S. J. McAlhany, T. D. Dang, and D. R. Rowley, “Stromal Expression of Connective Tissue Growth Factor Promotes Angiogenesis and Prostate Cancer Tumorigenesis,” Cancer Research 65, no. 19 (2005): 8887–8895.

[327] Y. Guo, J. L. Ayers, K. T. Carter, et al., “Senescence-associated Tissue Microenvironment Promotes Colon Cancer Formation Through the Secretory Factor GDF15,” Aging Cell 18, no. 6 (2019): e13013.

[328] M. Z. Gungor, M. Uysal, and S. Senturk, “The Bright and the Dark Side of TGF-β Signaling in Hepatocellular Carcinoma: Mechanisms, Dysregulation, and Therapeutic Implications,” Cancers (Basel) 14, no. 4 (2022): 940.

[329] M. A. Friese, J. Wischhusen, W. Wick, et al., “RNA Interference Targeting Transforming Growth Factor-beta Enhances NKG2D-mediated Antiglioma Immune Response, Inhibits Glioma Cell Migration and Invasiveness, and Abrogates Tumorigenicity in Vivo,” Cancer Research 64, no. 20 (2004): 7596–7603.

[330] L. Weng, J. Ye, F. Yang, et al., “TGF-β1/SMAD3 Regulates Programmed Cell Death 5 That Suppresses Cardiac Fibrosis Post-Myocardial Infarction by Inhibiting HDAC3,” Circulation Research 133, no. 3 (2023): 237–251.

[331] K. Ohuchida, K. Mizumoto, M. Murakami, et al., “Radiation to Stromal Fibroblasts Increases Invasiveness of Pancreatic Cancer Cells Through Tumor-stromal Interactions,” Cancer Research 64, no. 9 (2004): 3215–3222.

[332] L. Wang, E. Wang, J. Prado Balcazar, et al., “Chromatin Remodeling of Colorectal Cancer Liver Metastasis Is Mediated by an HGF-PU.1-DPP4 Axis,” Advanced science (Weinheim) 8, no. 19 (2021): e2004673.

[333] S. Yao, X. Liu, Y. Feng, et al., “Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment,” International Journal of Molecular Sciences 25, no. 16 (2024): 9101.

[334] X. Zheng, Z. Liu, J. Zhong, et al., “Downregulation of HINFP Induces Senescence-associated Secretory Phenotype to Promote Metastasis in a Non-cell-autonomous Manner in Bladder Cancer,” Oncogene 41, no. 28 (2022): 3587–3598.

[335] X. Wang, H. Wang, H. Yang, et al., “Tumor Necrosis Factor-α-and Interleukin-1β-dependent Matrix Metalloproteinase-3 Expression in Nucleus Pulposus Cells Requires Cooperative Signaling via Syndecan 4 and Mitogen-activated Protein Kinase-NF-κB Axis: Implications in Inflammatory Disc Disease,” American Journal of Pathology 184, no. 9 (2014): 2560–2572.

[336] L. E. Littlepage, M. D. Sternlicht, N. Rougier, et al., “Matrix Metalloproteinases Contribute Distinct Roles in Neuroendocrine Prostate Carcinogenesis, Metastasis, and Angiogenesis Progression,” Cancer Research 70, no. 6 (2010): 2224–2234.

[337] R. B. Ionescu, A. M. Nicaise, J. A. Reisz, et al., “Increased Cholesterol Synthesis Drives Neurotoxicity in Patient Stem Cell-derived Model of Multiple Sclerosis,” Cell Stem Cell 31, no. 11 (2024): 1574–1590. e11.

[338] D. Liu and P. J. Hornsby, “Senescent human Fibroblasts Increase the Early Growth of Xenograft Tumors via Matrix Metalloproteinase Secretion,” Cancer Research 67, no. 7 (2007): 3117–3126.

[339] M. Gabasa, E. S. Radisky, R. Ikemori, et al., “MMP1 drives Tumor Progression in Large Cell Carcinoma of the Lung Through Fibroblast Senescence,” Cancer Letters 507 (2021): 1–12.

[340] Y. Fu, Y. Xiang, H. Li, A. Chen, and Z. Dong, “Inflammation in Kidney Repair: Mechanism and Therapeutic Potential,” Pharmacology & Therapeutics 237 (2022): 108240.

[341] Y. Liu, H. Zhang, L. Yan, et al., “MMP-2 and MMP-9 Contribute to the Angiogenic Effect Produced by Hypoxia/15-HETE in Pulmonary Endothelial Cells,” Journal of Molecular and Cellular Cardiology 121 (2018): 36–50.

[342] S. Mariathasan, S. J. Turley, D. Nickles, et al., “TGFβ Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells,” Nature 554, no. 7693 (2018): 544–548.

[343] M. Ruscetti, J. Leibold, M. J. Bott, et al., “NK Cell-mediated Cytotoxicity Contributes to Tumor Control by a Cytostatic Drug Combination,” Science 362, no. 6421 (2018): 1416–1422.

[344] T. M. Bauer, A. Santoro, C. C. Lin, et al., “Phase I/Ib, Open-label, Multicenter, Dose-escalation Study of the Anti-TGF-β Monoclonal Antibody, NIS793, in Combination With spartalizumab in Adult Patients With Advanced Tumors,” Journal for ImmunoTherapy of Cancer 11, no. 11 (2023): e007353.

[345] A. Shinde, N. Chandak, J. Singh, et al., “TNF-α Induced NF-κB Mediated LYRM7 Expression Modulates the Tumor Growth and Metastatic Ability in Breast Cancer,” Free Radical Biology and Medicine 211 (2024): 158–170.

[346] J. Zhang, X. Wang, H. Liu, et al., “TNF-α Enhances Apoptosis by Promoting Chop Expression in Nucleus Pulposus Cells: Role of the MAPK and NF-κB Pathways,” Journal of Orthopaedic Research 37, no. 3 (2019): 697–705.

[347] P. Cui, W. Lu, J. Wang, et al., “Microglia/Macrophages Require Vitamin D Signaling to Restrain Neuroinflammation and Brain Injury in a murine Ischemic Stroke Model,” Journal of Neuroinflammation 20, no. 1 (2023): 63.

[348] T. Hofman, S. W. Ng, I. Garcés-Lázaro, F. Heigwer, M. Boutros, and A. Cerwenka, “IFNγ Mediates the Resistance of Tumor Cells to Distinct NK Cell Subsets,” Journal for ImmunoTherapy of Cancer 12, no. 7 (2024): e009410.

[349] P. Knopf, D. Stowbur, S. H. L. Hoffmann, et al., “Acidosis-mediated Increase in IFN-γ-induced PD-L1 Expression on Cancer Cells as an Immune Escape Mechanism in Solid Tumors,” Molecular cancer 22, no. 1 (2023): 207.

[350] V. Finisguerra, G. Di Conza, M. Di Matteo, et al., “MET Is Required for the Recruitment of Anti-tumoural Neutrophils,” Nature 522, no. 7556 (2015): 349–353.

[351] Y. Xie, A. Akpinarli, C. Maris, et al., “Naive Tumor-specific CD4(+) T Cells Differentiated in Vivo Eradicate Established Melanoma,” Journal of Experimental Medicine 207, no. 3 (2010): 651–667.

[352] Y. Jiang, Y. Zheng, Y. W. Zhang, et al., “Reciprocal Inhibition Between TP63 and STAT1 Regulates Anti-tumor Immune Response Through Interferon-γ Signaling in Squamous Cancer,” Nature Communications 15, no. 1 (2024): 2484.

[353] L. Beziaud, C. M. Young, A. M. Alonso, M. Norkin, A. R. Minafra, and J. Huelsken, “IFNγ-induced Stem-Like state of Cancer Cells as a Driver of Metastatic Progression Following Immunotherapy,” Cell Stem Cell 30, no. 6 (2023): 818–831. e6.

[354] O. Kann, F. Almouhanna, and B. Chausse, “Interferon γ: A Master Cytokine in Microglia-mediated Neural Network Dysfunction and Neurodegeneration,” Trends in Neuroscience (Tins) 45, no. 12 (2022): 913–927.

[355] A. Krtolica, S. Parrinello, S. Lockett, P. Y. Desprez, and J. Campisi, “Senescent Fibroblasts Promote Epithelial Cell Growth and Tumorigenesis: A Link Between Cancer and Aging,” Proceedings of the National Academy of Sciences of the United States of America 98, no. 21 (2001): 12072–12077.

[356] J. P. Coppé, C. K. Patil, F. Rodier, et al., “Senescence-associated Secretory Phenotypes Reveal Cell-nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor,” PLoS Biology 6, no. 12 (2008): 2853–2868.

[357] S. Parrinello, J. P. Coppe, A. Krtolica, and J. Campisi, “Stromal-epithelial Interactions in Aging and Cancer: Senescent Fibroblasts Alter Epithelial Cell Differentiation,” Journal of Cell Science 118, no. Pt 3 (2005): 485–496.

[358] E. Balentien, B. E. Mufson, R. L. Shattuck, R. Derynck, and A. Richmond, “Effects of MGSA/GRO Alpha on Melanocyte Transformation,” Oncogene 6, no. 7 (1991): 1115–1124.

[359] D. Tarallo, J. Martínez, A. Leyva, et al., “Mitofusin 1 Silencing Decreases the Senescent Associated Secretory Phenotype, Promotes Immune Cell Recruitment and Delays Melanoma Tumor Growth After Chemotherapy,” Scientific Reports 14, no. 1 (2024): 909.

[360] D. Daley, V. R. Mani, N. Mohan, et al., “Dectin 1 Activation on Macrophages by Galectin 9 Promotes Pancreatic Carcinoma and Peritumoral Immune Tolerance,” Nature Medicine 23, no. 5 (2017): 556–567.

[361] K. Kawaguchi, K. Komoda, R. Mikawa, A. Asai, and M. Sugimoto, “Cellular Senescence Promotes Cancer Metastasis by Enhancing Soluble E-cadherin Production,” Iscience 24, no. 9 (2021): 103022.

[362] Y. Ma, Y. Liang, N. Liang, Y. Zhang, and F. Xiao, “Identification and Functional Analysis of Senescence-associated Secretory Phenotype of Premature Senescent Hepatocytes Induced by Hexavalent Chromium,” Ecotoxicology and Environmental Safety 211 (2021): 111908.

[363] M. Takasugi, R. Okada, A. Takahashi, D. Virya Chen, S. Watanabe, and E. Hara, “Small Extracellular Vesicles Secreted From Senescent Cells Promote Cancer Cell Proliferation Through EphA2,” Nature Communications 8 (2017): 15729.

[364] J. Ye, J. M. Baer, D. V. Faget, et al., “Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression,” Cancer Discovery 14, no. 7 (2024): 1302–1323.

[365] G. Eisele, J. Wischhusen, M. Mittelbronn, et al., “TGF-beta and Metalloproteinases Differentially Suppress NKG2D Ligand Surface Expression on Malignant Glioma Cells,” Brain 129, no. Pt 9 (2006): 2416–2425.

[366] M. B. Fuertes, C. I. Domaica, and N. W. Zwirner, “Leveraging NKG2D Ligands in Immuno-Oncology,” Frontiers in Immunology 12 (2021): 713158.

[367] P. R. Nath, D. Pal-Nath, A. Mandal, M. C. Cam, A. L. Schwartz, and D. D. Roberts, “Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment,” Cancer Immunology Research 7, no. 9 (2019): 1547–1561.

[368] W. Chen, “TGF-β Regulation of T Cells,” Annual Review of Immunology 41 (2023): 483–512.

[369] R. Cheong, A. Bergmann, S. L. Werner, J. Regal, A. Hoffmann, and A. Levchenko, “Transient IkappaB Kinase Activity Mediates Temporal NF-kappaB Dynamics in Response to a Wide Range of Tumor Necrosis Factor-alpha Doses,” Journal of Biological Chemistry 281, no. 5 (2006): 2945–2950.

[370] C. Cantoni, M. Falco, M. Vitale, et al., “Human NK Cells and Cancer,” Oncoimmunology 13, no. 1 (2024): 2378520.

[371] C. A. Schmitt, B. Wang, and M. Demaria, “Senescence and Cancer—role and Therapeutic Opportunities,” Nature reviews Clinical Oncology 19, no. 10 (2022): 619–636.

[372] T. Welte, I. S. Kim, L. Tian, et al., “Oncogenic mTOR Signalling Recruits Myeloid-derived Suppressor Cells to Promote Tumour Initiation,” Nature Cell Biology 18, no. 6 (2016): 632–644.

[373] T. Iwata, Y. Kondo, O. Kimura, et al., “PD-L1(+)MDSCs Are Increased in HCC Patients and Induced by Soluble Factor in the Tumor Microenvironment,” Scientific Reports 6 (2016): 39296.

[374] K. Huang, W. Luo, J. Fang, et al., “Notch3 signaling Promotes Colorectal Tumor Growth by Enhancing Immunosuppressive Cells Infiltration in the Microenvironment,” BMC Cancer 23, no. 1 (2023): 55.

[375] P. Lai, L. Liu, N. Bancaro, et al., “Mitochondrial DNA Released by Senescent Tumor Cells Enhances PMN-MDSC-driven Immunosuppression Through the cGAS-STING Pathway,” Immunity 58, no. 4 (2025): 811–825. e7.

[376] J. Hsu, J. J. Hodgins, M. Marathe, et al., “Contribution of NK Cells to Immunotherapy Mediated by PD-1/PD-L1 Blockade,” Journal of Clinical Investigation 128, no. 10 (2018): 4654–4668.

[377] S. Joshi and A. Sharabi, “Targeting Myeloid-derived Suppressor Cells to Enhance Natural Killer Cell-based Immunotherapy,” Pharmacology & Therapeutics 235 (2022): 108114.

[378] A. Zoso, E. M. Mazza, S. Bicciato, et al., “Human Fibrocytic Myeloid-derived Suppressor Cells Express IDO and Promote Tolerance via Treg-cell Expansion,” European Journal of Immunology 44, no. 11 (2014): 3307–3319.

[379] B. Pang, Y. Zhen, C. Hu, Z. Ma, S. Lin, and H. Yi, “Myeloid-derived Suppressor Cells Shift Th17/Treg Ratio and Promote Systemic Lupus Erythematosus Progression Through Arginase-1/miR-322-5p/TGF-β Pathway,” Clinical Science (London, England: 1979) 134, no. 16 (2020): 2209–2222.

[380] Y. H. Chen, X. Zhang, C. H. Chou, et al., “Association of Dipeptidylpeptidase 4 (CD26) with Chondrocyte Senescence and Radiographic Progression in Knee Osteoarthritis,” Arthritis & Rheumatology 75, no. 7 (2023): 1120–1131.

[381] X. Li, M. Chen, X. Chen, et al., “TRAP1 drives Smooth Muscle Cell Senescence and Promotes Atherosclerosis via HDAC3-primed Histone H4 Lysine 12 Lactylation,” European Heart Journal 45, no. 39 (2024): 4219–4235.

[382] Y. C. Shih, H. F. Chen, C. Y. Wu, et al., “The Phosphatase DUSP22 Inhibits UBR2-mediated K63-ubiquitination and Activation of Lck Downstream of TCR Signalling,” Nature Communications 15, no. 1 (2024): 532.

[383] C. E. DeSantis, K. D. Miller, W. Dale, et al., “Cancer Statistics for Adults Aged 85 Years and Older, 2019,” CA: A Cancer Journal for Clinicians 69, no. 6 (2019): 452–467.

[384] F. A. Pelissier Vatter, D. Schapiro, and H. Chang, “High-Dimensional Phenotyping Identifies Age-Emergent Cells in Human Mammary Epithelia,” Cell Reports 23, no. 4 (2018): 1205–1219.

[385] M. D. Park, J. Le Berichel, and P. Hamon, “Hematopoietic Aging Promotes Cancer by Fueling IL-1 α-driven Emergency Myelopoiesis,” Science (2024): eadn0327.

[386] M. J. Yousefzadeh, R. R. Flores, Y. Zhu, et al., “An Aged Immune System Drives Senescence and Ageing of Solid Organs,” Nature 594, no. 7861 (2021): 100–105.

[387] Y. Han, Y. Y. Zhang, Y. Q. Pan, et al., “IL-1β-associated NNT Acetylation Orchestrates Iron-sulfur Cluster Maintenance and Cancer Immunotherapy Resistance,” Molecular Cell 83, no. 11 (2023): 1887–1902.

[388] M. D. Park, J. Le Berichel, and P. Hamon, “Hematopoietic Aging Promotes Cancer by Fueling IL-1 α-driven Emergency Myelopoiesis,” Science 386, no. 6720 (2024): eadn0327.

[389] C. A. Dinarello, “Immunological and Inflammatory Functions of the Interleukin-1 family,” Annual Review of Immunology 27 (2009): 519–550.

[390] X. Jiang, J. Wang, X. Deng, et al., “The Role of Microenvironment in Tumor Angiogenesis,” Journal of Experimental & Clinical Cancer Research 39, no. 1 (2020): 204.

[391] M. Dong, L. Yang, M. Qu, et al., “Autocrine IL-1β Mediates the Promotion of Corneal Neovascularization by Senescent Fibroblasts,” American Journal of Physiology Cell Physiology 315, no. 5 (2018): C734–c743.

[392] S. Chen, S. Zhang, Y. Shi, and X. Liu, “Microenvironment Crosstalk and Immune Evasion of Circulating Tumor Cells: From Mechanism to Clinical Significance,” Chinese Medical Journal (2025).

[393] L. Zhang, J. Ma, J. Zhang, et al., “Radiotherapy-Associated Cellular Senescence and EMT Alterations Contribute to Distinct Disease Relapse Patterns in Locally Advanced Cervical Cancer,” Advanced science (Weinheim) (2025): e2412574.

[394] X. Liu, F. Zuo, J. Song, et al., “Immune Checkpoints HLA-E:CD94-NKG2A and HLA-C:KIR2DL1 Complementarily Shield Circulating Tumor Cells From NK-mediated Immune Surveillance,” Cell Discovery 10, no. 1 (2024): 16.

[395] M. Terekhova, A. Swain, P. Bohacova, et al., “Single-cell Atlas of Healthy human Blood Unveils Age-related Loss of NKG2C(+)GZMB(-)CD8(+) Memory T Cells and Accumulation of Type 2 Memory T Cells,” Immunity 56, no. 12 (2023): 2836–2854. e9.

[396] A. Kaur, M. R. Webster, K. Marchbank, et al., “sFRP2 in the Aged Microenvironment Drives Melanoma Metastasis and Therapy Resistance,” Nature 532, no. 7598 (2016): 250–254.

[397] S. Gerstberger, Q. Jiang, and K. Ganesh, “Metastasis,” Cell 186, no. 8 (2023): 1564–1579.

[398] R. Duan, L. Jiang, T. Wang, et al., “Aging-induced Immune Microenvironment Remodeling Fosters Melanoma in Male Mice via gammadelta17-Neutrophil-CD8 Axis,” Nature Communications 15, no. 1 (2024): 10860.

[399] E. Risson, A. R. Nobre, V. Maguer-Satta, and J. A. Aguirre-Ghiso, “The Current Paradigm and Challenges Ahead for the Dormancy of Disseminated Tumor Cells,” Nature Cancer 1, no. 7 (2020): 672–680.

[400] A. Singh, V. Veeriah, P. Xi, et al., “Angiocrine Signals Regulate Quiescence and Therapy Resistance in Bone Metastasis,” JCI Insight 4, no. 13 (2019): e125679.

[401] A. L. Correia, J. C. Guimaraes, P. Auf der Maur, et al., “Hepatic Stellate Cells Suppress NK Cell-sustained Breast Cancer Dormancy,” Nature 594, no. 7864 (2021): 566–571.

[402] X. Li, P. Ramadori, D. Pfister, M. Seehawer, L. Zender, and M. Heikenwalder, “The Immunological and Metabolic Landscape in Primary and Metastatic Liver Cancer,” Nature Reviews Cancer 21, no. 9 (2021): 541–557.

[403] S. Zhao, H. Zhao, W. Yang, and L. Zhang, “The next Generation of Immunotherapies for Lung Cancers,” Nature reviews Clinical oncology 22, no. 8 (2025): 592–616.

[404] A. Moreira, S. Gross, M. C. Kirchberger, M. Erdmann, G. Schuler, and L. Heinzerling, “Senescence Markers: Predictive for Response to Checkpoint Inhibitors,” International Journal of Cancer 144, no. 5 (2019): 1147–1150.

[405] J. Yin, Y. Song, Y. Fu, et al., “The Efficacy of Immune Checkpoint Inhibitors Is Limited in Elderly NSCLC: A Retrospective Efficacy Study and Meta-analysis,” Aging (Albany NY) 15, no. 24 (2023): 15025–15049.

[406] D. Salas-Benito, I. Eguren-Santamaria, and M. F. Sanmamed, “Senescent T Cells as a Resistance Mechanism to Lung Cancer Immunotherapy,” Clinical Cancer Research 27, no. 2 (2021): 374–376.

[407] H. Song, L. Chen, X. Pan, et al., “Targeting Tumor Monocyte-intrinsic PD-L1 by Rewiring STING Signaling and Enhancing STING Agonist Therapy,” Cancer Cell 43, no. 3 (2025): 503–518. e10.

[408] D. Zhao, Y. Wang, N. D. Wong, and J. Wang, “Impact of Aging on Cardiovascular Diseases: From Chronological Observation to Biological Insights: JACC Family Series,” JACC Asia 4, no. 5 (2024): 345–358.

[409] X. Wang, L. Chen, J. Wei, et al., “The Immune System in Cardiovascular Diseases: From Basic Mechanisms to Therapeutic Implications,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 166.

[410] X. Li, Y. Bao, N. Zhang, et al., “Senescent CD8+ T Cells: A Novel Risk Factor in Atrial Fibrillation,” Cardiovascular Research 121, no. 1 (2025): 97–112.

[411] J. C. Youn, H. T. Yu, B. J. Lim, et al., “Immunosenescent CD8+ T Cells and C-X-C Chemokine Receptor Type 3 Chemokines Are Increased in human Hypertension,” Hypertension 62, no. 1 (2013): 126–133.

[412] L. Gackowska, J. Michałkiewicz, A. Niemirska, et al., “Loss of CD31 Receptor in CD4+ and CD8+ T-cell Subsets in Children With Primary Hypertension Is Associated With Hypertension Severity and Hypertensive Target Organ Damage,” Journal of Hypertension 36, no. 11 (2018): 2148–2156.

[413] V. Smit, J. de Mol, F. H. Schaftenaar, et al., “Single-cell Profiling Reveals Age-associated Immunity in Atherosclerosis,” Cardiovascular Research 119, no. 15 (2023): 2508–2521.

[414] F. Fang, C. Xiao, C. Li, X. Liu, and S. Li, “Tuning Macrophages for Atherosclerosis Treatment,” Regen Biomater 10 (2023): rbac103.

[415] Y. Wang, Y. Zheng, X. Liang, et al., “α-Lipoic Acid Alleviate Myocardial Infarction by Suppressing Age-independent Macrophage Senescence,” Scientific Reports 15, no. 1 (2025): 11996.

[416] Q. Jiang, J. Liu, S. Huang, et al., “Antiageing Strategy for Neurodegenerative Diseases: From Mechanisms to Clinical Advances,” Signal Transduction and Targeted Therapy 10, no. 1 (2025): 76.

[417] G. Livingston, J. Huntley, A. Sommerlad, et al., “Dementia Prevention, Intervention, and Care: 2020 Report of the Lancet Commission,” Lancet 396, no. 10248 (2020): 413–446.

[418] H. J. Shin, I. S. Kim, S. G. Choi, et al., “Rejuvenating Aged Microglia by p16(ink4a)-siRNA-loaded Nanoparticles Increases Amyloid-β Clearance in Animal Models of Alzheimer's Disease,” Molecular Neurodegeneration 19, no. 1 (2024): 25.

[419] V. Tiwari, B. Prajapati, Y. Asare, et al., “Innate Immune Training Restores Pro-reparative Myeloid Functions to Promote Remyelination in the Aged central Nervous System,” Immunity 57, no. 9 (2024): 2173–2190. e8.

[420] N. Rachmian, S. Medina, U. Cherqui, et al., “Identification of Senescent, TREM2-expressing Microglia in Aging and Alzheimer's Disease Model Mouse Brain,” Nature Neuroscience 27, no. 6 (2024): 1116–1124.

[421] T. J. Bussian, A. Aziz, C. F. Meyer, B. L. Swenson, J. M. van Deursen, and D. J. Baker, “Clearance of Senescent Glial Cells Prevents Tau-dependent Pathology and Cognitive Decline,” Nature 562, no. 7728 (2018): 578–582.

[422] S. Takatori, M. Kondo, and T. Tomita, “Unraveling the Complex Role of Microglia in Alzheimer's Disease: Amyloid β Metabolism and Plaque Formation,” Inflamm Regen 45, no. 1 (2025): 16.

[423] L. Wei, X. Yang, J. Wang, et al., “H3K18 lactylation of Senescent Microglia Potentiates Brain Aging and Alzheimer's Disease Through the NFκB Signaling Pathway,” Journal of Neuroinflammation 20, no. 1 (2023): 208.

[424] S. A. Liddelow, K. A. Guttenplan, L. E. Clarke, et al., “Neurotoxic Reactive Astrocytes Are Induced by Activated Microglia,” Nature 541, no. 7638 (2017): 481–487.

[425] X. Xie, G. Ma, X. Li, J. Zhao, Z. Zhao, and J. Zeng, “Activation of Innate Immune cGAS-STING Pathway Contributes to Alzheimer's Pathogenesis in 5×FAD Mice,” Nature Aging 3, no. 2 (2023): 202–212.

[426] B. R. Bloem, M. S. Okun, and C. Klein, “Parkinson's Disease,” Lancet 397, no. 10291 (2021): 2284–2303.

[427] W. Poewe, K. Seppi, C. M. Tanner, et al., “Parkinson Disease,” Nature reviews Disease primers 3 (2017): 17013.

[428] A. di Domenico, G. Carola, C. Calatayud, et al., “Patient-Specific iPSC-Derived Astrocytes Contribute to Non-Cell-Autonomous Neurodegeneration in Parkinson's Disease,” Stem Cell Reports 12, no. 2 (2019): 213–229.

[429] E. C. Wright-Jin and D. H. Gutmann, “Microglia as Dynamic Cellular Mediators of Brain Function,” Trends in Molecular Medicine 25, no. 11 (2019): 967–979.

[430] S. Smajić, C. A. Prada-Medina, Z. Landoulsi, et al., “Single-cell Sequencing of human Midbrain Reveals Glial Activation and a Parkinson-specific Neuronal state,” Brain 145, no. 3 (2022): 964–978.

[431] H. Scheiblich, L. Bousset, S. Schwartz, et al., “Microglial NLRP3 Inflammasome Activation Upon TLR2 and TLR5 Ligation by Distinct α-Synuclein Assemblies,” Journal of Immunology 207, no. 8 (2021): 2143–2154.

[432] Y. Guo, X. Wei, H. Yan, et al., “TREM2 deficiency Aggravates α-synuclein-induced Neurodegeneration and Neuroinflammation in Parkinson's disease Models,” Faseb Journal 33, no. 11 (2019): 12164–12174.

[433] Y. Xu, Z. An, and K. Hou, “ACE2 Alleviates Microglia Neuroinflammation by RANK-RANKL-OPG Axis in Parkinson's Disease,” Inflammation (2025).

[434] E. Gerasimova, A. C. Beenen, D. Kachkin, et al., “Novel co-culture Model of T Cells and Midbrain Organoids for Investigating Neurodegeneration in Parkinson's Disease,” NPJ Parkinson's Disease 11, no. 1 (2025): 36.

[435] Y. Xu, Y. Li, C. Wang, et al., “The Reciprocal Interactions Between Microglia and T Cells in Parkinson's disease: A Double-edged Sword,” Journal of Neuroinflammation 20, no. 1 (2023): 33.

[436] G. S. Cooper, M. L. Bynum, and E. C. Somers, “Recent Insights in the Epidemiology of Autoimmune Diseases: Improved Prevalence Estimates and Understanding of Clustering of Diseases,” Journal of Autoimmunity 33, no. 3-4 (2009): 197–207.

[437] D. C. Tian, C. Zhang, M. Yuan, et al., “Incidence of Multiple Sclerosis in China: A Nationwide Hospital-based Study,” The Lancet Regional Health Western Pacific 1 (2020): 100010.

[438] G. Comi, A. Bar-Or, H. Lassmann, et al., “Role of B Cells in Multiple Sclerosis and Related Disorders,” Annals of Neurology 89, no. 1 (2021): 13–23.

[439] B. Arneth, “Contributions of T Cells in Multiple Sclerosis: What Do We Currently Know?,” Journal of Neurology 268, no. 12 (2021): 4587–4593.

[440] B. Zierfuss, C. Larochelle, and A. Prat, “Blood-brain Barrier Dysfunction in Multiple Sclerosis: Causes, Consequences, and Potential Effects of Therapies,” The Lancet Neurology 23, no. 1 (2024): 95–109.

[441] P. S. Rommer, G. Bsteh, T. Zrzavy, R. Hoeftberger, and T. Berger, “Immunosenescence in Neurological Diseases-Is There Enough Evidence?,” Biomedicines 10, no. 11 (2022): 2864.

[442] C. López-Otín, M. A. Blasco, L. Partridge, M. Serrano, and G. Kroemer, “Hallmarks of Aging: An Expanding Universe,” Cell 186, no. 2 (2023): 243–278.

[443] B. Neumann, M. Segel, K. J. Chalut, and R. J. Franklin, “Remyelination and Ageing: Reversing the Ravages of Time,” Multiple Sclerosis 25, no. 14 (2019): 1835–1841.

[444] K. M. Krysko, R. G. Henry, B. A. C. Cree, et al., “Telomere Length Is Associated With Disability Progression in Multiple Sclerosis,” Annals of Neurology 86, no. 5 (2019): 671–682.

[445] F. Bridge, H. Butzkueven, A. Van der Walt, and V. G. Jokubaitis, “The Impact of Menopause on Multiple Sclerosis,” Autoimmunity Reviews 22, no. 8 (2023): 103363.

[446] J. S. Smolen, D. Aletaha, A. Barton, et al., “Rheumatoid Arthritis,” Nature Reviews Disease Primers 4 (2018): 18001.

[447] M. van Onna and A. Boonen, “The Challenging Interplay Between Rheumatoid Arthritis, Ageing and Comorbidities,” BMC Musculoskeletal Disorders 17 (2016): 184.

[448] M. E. Bauer, “Accelerated Immunosenescence in Rheumatoid Arthritis: Impact on Clinical Progression,” Immunity & Ageing: I & A 17 (2020): 6.

[449] F. Sallusto, D. Lenig, R. Förster, M. Lipp, and A. Lanzavecchia, “Two Subsets of Memory T Lymphocytes With Distinct Homing Potentials and Effector Functions,” Nature 401, no. 6754 (1999): 708–712.

[450] Global Burden of 288 Causes of Death and Life Expectancy Decomposition in 204 Countries and territories and 811 Subnational Locations, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021. Lancet 2024;403(10440):2100–2132.

[451] R. Chen, J. Zou, J. Chen, L. Wang, R. Kang, and D. Tang, “Immune Aging and Infectious Diseases,” Chinese Medical Journal 137, no. 24 (2024): 3010–3049.

[452] D. Curran, A. Callegaro, K. Fahrbach, et al., “Meta-Regression of Herpes Zoster Incidence Worldwide,” Infectious Diseases and Therapy 11, no. 1 (2022): 389–403.

[453] P. Zhu, X. Hao, W. Wang, et al., “Incidence and Risk Factors of Active Tuberculosis Among Older Individuals With Latent Tuberculosis Infection: A Cohort Study in Two High-epidemic Sites in Eastern China,” Frontiers in Cellular and Infection Microbiology 14 (2024): 1332211.

[454] S. C. Ugbaja, S. A. Omerigwe, S. M. Z. Ndlovu, M. Ngcobo, and N. Gqaleni, “Evaluating the Efficacy of Repurposed Antiretrovirals in Hepatitis B Virus Treatment: A Narrative Review of the Pros and Cons,” International Journal of Molecular Sciences 26, no. 3 (2025): 925.

[455] C. K. Dye, H. Wu, G. L. Jackson, et al., “Epigenetic Aging in Older People Living With HIV in Eswatini: A Pilot Study of HIV and Lifestyle Factors and Epigenetic Aging,” Research Square (2023).

[456] A. Y. Y. Hsieh, R. Cai, N. F. Bernard, C. L. Tremblay, and H. C. F. Côté, “Evidence of Greater Immune Aging Among Untreated HIV Slow Progressors Than Antiretroviral-controlled People Living With HIV,” Journal of Infection 91, no. 1 (2025): 106511.

[457] T. Tsukamoto, “Hematopoietic Stem/Progenitor Cells and the Pathogenesis of HIV/AIDS,” Frontiers in Cellular and Infection Microbiology 10 (2020): 60.

[458] V. Bordoni, M. Bibas, D. Viola, et al., “Bone Marrow CD34(+) Progenitor Cells From HIV-Infected Patients Show an Impaired T Cell Differentiation Potential Related to Proinflammatory Cytokines,” Aids Research and Human Retroviruses 33, no. 6 (2017): 590–596.

[459] Q. Xiao, F. Yu, L. Yan, et al., “The CD4/CD8 Ratio Is Associated With T Lymphocyte Functions in Long-term Virally Suppressed Patients With HIV,” BMC Infectious Diseases [Electronic Resource] 25, no. 1 (2025): 76.

[460] R. Zhao, H. Kou, D. Jiang, and F. Wang, “Exploring the Anti-aging Effects of Fisetin in Telomerase-deficient Progeria Mouse Model,” PeerJ 11 (2023): e16463.

[461] X. Wang, Y. Xue, L. Li, et al., “PRMT3 reverses HIV-1 Latency by Increasing Chromatin Accessibility to Form a TEAD4-P-TEFb-containing Transcriptional Hub,” Nature Communications 16, no. 1 (2025): 4529.

[462] S. Naik and E. Fuchs, “Inflammatory Memory and Tissue Adaptation in Sickness and in Health,” Nature 607, no. 7918 (2022): 249–255.

[463] H. Y. Zheng, X. H. Wang, X. Y. He, et al., “Aging Induces Severe SIV Infection Accompanied by an Increase in Follicular CD8+ T Cells With Overactive STAT3 Signaling,” Cellular & Molecular Immunology 19, no. 9 (2022): 1042–1053.

[464] O. Takeuchi and S. Akira, “Pattern Recognition Receptors and Inflammation,” Cell 140, no. 6 (2010): 805–820.

[465] W. Zhong, Z. Rao, J. Xu, et al., “Defective Mitophagy in Aged Macrophages Promotes Mitochondrial DNA Cytosolic Leakage to Activate STING Signaling During Liver Sterile Inflammation,” Aging Cell 21, no. 6 (2022): e13622.

[466] G. Sun, K. Li, J. Ping, et al., “A Single-cell Transcriptomic Atlas Reveals Senescence and Inflammation in the Post-tuberculosis human Lung,” Nature microbiology 10, no. 8 (2025): 2073–2091.

[467] L. Hou, X. Feng, Z. Zhu, et al., “IGFBPL1 inhibits Macrophage Lipid Accumulation by Enhancing the Activation of IGR1R/LXRα/ABCG1 Pathway,” Aging (Albany NY) 15, no. 24 (2023): 14791–14802.

[468] E. Chang, K. Cavallo, and S. M. Behar, “CD4 T Cell Dysfunction Is Associated With Bacterial Recrudescence During Chronic Tuberculosis,” Nature Communications 16, no. 1 (2025): 2636.

[469] P. S. Minhas, A. Latif-Hernandez, M. R. McReynolds, et al., “Restoring Metabolism of Myeloid Cells Reverses Cognitive Decline in Ageing,” Nature 590, no. 7844 (2021): 122–128.

[470] J. Zhao, L. Wu, G. Cai, et al., “Targeting PGE2 Mediated Senescent Neuron Improves Tumour Therapy,” Neuro-Oncology 27, no. 6 (2025): 1491–1506.

[471] X. Liu, M. Yang, P. Xu, et al., “Kynurenine-AhR Reduces T-cell Infiltration and Induces a Delayed T-cell Immune Response by Suppressing the STAT1-CXCL9/CXCL10 Axis in Tuberculosis,” Cellular & Molecular Immunology 21, no. 12 (2024): 1426–1440.

[472] J. Litt, A. L. Cunningham, F. Arnalich-Montiel, and R. Parikh, “Herpes Zoster Ophthalmicus: Presentation, Complications, Treatment, and Prevention,” Infectious Diseases and Therapy 13, no. 7 (2024): 1439–1459.

[473] S. Mangmee, S. Kardkarnklai, S. Phuphanitcharoenkun, et al., “Characterization of Neutralizing versus Binding Antibody and T Cell Responses to Varicella-zoster Virus in the Elderly,” Scientific Reports 15, no. 1 (2025): 13776.

[474] Q. Peng, X. Guo, Y. Luo, et al., “Dynamic Immune Landscape and VZV-Specific T Cell Responses in Patients with Herpes Zoster and Postherpetic Neuralgia,” Frontiers in Immunology 13 (2022): 887892.

[475] S. W. Sun, C. Qi, and X. Z. Xiong, “Challenges of COPD Patients During the COVID-19 Pandemic,” Pathogens (Basel, Switzerland) 11, no. 12 (2022): 1484.

[476] J. Jubrail, N. Kurian, and F. Niedergang, “Macrophage Phagocytosis Cracking the Defect Code in COPD,” Biomedical Journal 40, no. 6 (2017): 305–312.

[477] Y. Qi, Yan, D. Tang, et al., “Inflammatory and Immune Mechanisms in COPD: Current Status and Therapeutic Prospects,” Journal of Inflammation Research 17 (2024): 6603–6618.

[478] M. Schuliga, J. Read, and D. A. Knight, “Ageing Mechanisms That Contribute to Tissue Remodeling in Lung Disease,” Ageing Research Reviews 70 (2021): 101405.

[479] Y. Jin, Y. Wan, G. Chen, et al., “Treg/IL-17 Ratio and Treg Differentiation in Patients With COPD,” PLoS ONE 9, no. 10 (2014): e111044.

[480] A. B. Villaseñor-Altamirano, D. Jain, Y. Jeong, et al., “Activation of CD8(+) T Cells in Chronic Obstructive Pulmonary Disease Lung,” American Journal of Respiratory and Critical Care Medicine 208, no. 11 (2023): 1177–1195.

[481] D. J. Magliano and E. J. Boyko, “committee IDFDAtes. IDF Diabetes Atlas,” Idf Diabetes Atlas (International Diabetes Federation. © International Diabetes Federation, 2021, 2021).

[482] N. Lascar, J. Brown, H. Pattison, A. H. Barnett, C. J. Bailey, and S. Bellary, “Type 2 Diabetes in Adolescents and Young Adults,” The Lancet Diabetes & Endocrinology 6, no. 1 (2018): 69–80.

[483] A. K. Palmer, B. Gustafson, J. L. Kirkland, and U. Smith, “Cellular Senescence: At the Nexus Between Ageing and Diabetes,” Diabetologia 62, no. 10 (2019): 1835–1841.

[484] D. T. Brunelli, V. O. Boldrini, I. L. P. Bonfante, et al., “Obesity Increases Gene Expression of Markers Associated with Immunosenescence in Obese Middle-Aged Individuals,” Frontiers in Immunology 12 (2021): 806400.

[485] B. C. Sim, Y. E. Kang, S. K. You, et al., “Hepatic T-cell Senescence and Exhaustion Are Implicated in the Progression of Fatty Liver Disease in Patients With Type 2 Diabetes and Mouse Model With Nonalcoholic Steatohepatitis,” Cell Death & Disease 14, no. 9 (2023): 618.

[486] L. A. Callender, E. C. Carroll, C. Garrod-Ketchley, et al., “Altered Nutrient Uptake Causes Mitochondrial Dysfunction in Senescent CD8(+) EMRA T Cells during Type 2 Diabetes,” Frontiers in Aging 2 (2021): 681428.

[487] C. Y. Westwell-Roper, J. A. Ehses, and C. B. Verchere, “Resident Macrophages Mediate Islet Amyloid Polypeptide-induced Islet IL-1β Production and β-cell Dysfunction,” Diabetes 63, no. 5 (2014): 1698–1711.

[488] D. Suchy, K. Łabuzek, Ł. Bułdak, D. Szkudłapski, and B. Okopień, “Corrigendum to "Comparison of Chosen Activation Markers of human Monocytes/Macrophages Isolated From the Peripheral Blood of Young and Elderly Volunteers''. Pharmacol. Rep. 66 (2014) 759-765],” Pharmacological Reports: PR 71, no. 5 (2019): 983–984.

[489] L. Homann, M. Rentschler, E. Brenner, K. Böhm, M. Röcken, and T. Wieder, “IFN-γ and TNF Induce Senescence and a Distinct Senescence-Associated Secretory Phenotype in Melanoma,” Cells 11, no. 9 (2022): 1514.

[490] H. Wu and C. M. Ballantyne, “Metabolic Inflammation and Insulin Resistance in Obesity,” Circulation Research 126, no. 11 (2020): 1549–1564.

[491] H. S. Yi, S. Y. Kim, J. T. Kim, et al., “T-cell Senescence Contributes to Abnormal Glucose Homeostasis in Humans and Mice,” Cell Death & Disease 10, no. 3 (2019): 249.

[492] Y. H. Lee, S. R. Kim, D. H. Han, et al., “Senescent T Cells Predict the Development of Hyperglycemia in Humans,” Diabetes 68, no. 1 (2019): 156–162.

[493] A. S. Kulkarni, S. Gubbi, and N. Barzilai, “Benefits of Metformin in Attenuating the Hallmarks of Aging,” Cell metabolism 32, no. 1 (2020): 15–30.

[494] W. J. Jin, L. M. Zangl, M. Hyun, et al., “ATM Inhibition Augments Type I Interferon Response and Antitumor T-cell Immunity When Combined With Radiation Therapy in Murine Tumor Models,” Journal for ImmunoTherapy of Cancer 11, no. 9 (2023): e007474.

[495] A. Lanna, S. M. Henson, D. Escors, and A. N. Akbar, “The Kinase p38 Activated by the Metabolic Regulator AMPK and Scaffold TAB1 Drives the Senescence of human T Cells,” Nature Immunology 15, no. 10 (2014): 965–972.

[496] Z. Yang, X. Liu, J. Zhu, et al., “Inhibiting Intracellular CD28 in Cancer Cells Enhances Antitumor Immunity and Overcomes Anti-PD-1 Resistance via Targeting PD-L1,” Cancer Cell 43, no. 1 (2025): 86–102. e10.

[497] J. Yang, H. C. Liu, J. Q. Zhang, et al., “The Effect of Metformin on Senescence of T Lymphocytes,” Immunity & Ageing 20, no. 1 (2023): 73.

[498] P. Chaturvedi, V. George, N. Shrestha, et al., “Immunotherapeutic HCW9218 Augments Anti-tumor Activity of Chemotherapy via NK Cell-mediated Reduction of Therapy-induced Senescent Cells,” Molecular Therapy 30, no. 3 (2022): 1171–1187.

[499] D. Zhivaki, S. N. Kennedy, J. Park, et al., “Correction of Age-associated Defects in Dendritic Cells Enables CD4(+) T Cells to Eradicate Tumors,” Cell 187, no. 15 (2024): 3888–3903. e18.

[500] Z. W. Lai, R. Kelly, T. Winans, et al., “Sirolimus in Patients With Clinically Active Systemic Lupus Erythematosus Resistant to, or Intolerant of, Conventional Medications: A Single-arm, Open-label, Phase 1/2 Trial,” Lancet 391, no. 10126 (2018): 1186–1196.

[501] A. Naser Moghadasi, F. Ashtari, and S. M. Baghbanian, “Safety and Effectiveness of Cinnomer(®) on Disease Characteristics, Depression, and Quality of Life of Patients With Multiple Sclerosis: A Phase IV, Post-marketing, Prospective, Multicenter Study,” Archives of Iranian Medicine 26, no. 11 (2023): 647–653.

[502] B. Assouline, R. Kahn, L. Hodali, et al., “Senescent Cancer-associated Fibroblasts in Pancreatic Adenocarcinoma Restrict CD8(+) T Cell Activation and Limit Responsiveness to Immunotherapy in Mice,” Nature Communications 15, no. 1 (2024): 6162.

[503] H. Wang, S. Yuan, Q. Zheng, et al., “Dual Inhibition of CDK4/6 and XPO1 Induces Senescence with Acquired Vulnerability to CRBN-Based PROTAC Drugs,” Gastroenterology 166, no. 6 (2024): 1130–1144. e8.

[504] F. Li, P. Liu, and W. Mi, “Blocking Methionine Catabolism Induces Senescence and Confers Vulnerability to GSK3 Inhibition in Liver Cancer,” Nature Cancer 5, no. 1 (2024): 131–146.

[505] P. Zhang, Y. Kishimoto, I. Grammatikakis, et al., “Senolytic Therapy Alleviates Aβ-associated Oligodendrocyte Progenitor Cell Senescence and Cognitive Deficits in an Alzheimer's Disease Model,” Nature Neuroscience 22, no. 5 (2019): 719–728.

[506] W. Ji, H. Zhou, W. Liang, et al., “SSK1-Loaded Neurotransmitter-Derived Nanoparticles for Alzheimer's Disease Therapy via Clearance of Senescent Cells,” Small 20, no. 26 (2024): e2308574.

[507] S. I. Graves, C. F. Meyer, K. B. Jeganathan, and D. J. Baker, “p16-expressing Microglia and Endothelial Cells Promote Tauopathy and Neurovascular Abnormalities in PS19 Mice,” Neuron 113, no. 14 (2025): 2251–2264.

[508] H. Zhu, J. Jiang, M. Yang, et al., “Topical Application of a BCL-2 Inhibitor Ameliorates Imiquimod-induced Psoriasiform Dermatitis by Eliminating Senescent Cells,” Journal of Dermatological Science 115, no. 2 (2024): 54–63.

[509] Y. Zhao, X. Y. Zhu, W. Ma, et al., “Cellular Senescence Promotes Macrophage-to-myofibroblast Transition in Chronic Ischemic Renal Disease,” Cell Death & Disease 16, no. 1 (2025): 372.

[510] Y. Xia, J. Li, L. Wang, et al., “Engineering Hierarchical Recognition-Mediated Senolytics for Reliable Regulation of Cellular Senescence and Anti-Atherosclerosis Therapy,” Angewandte Chemie (International ed in English) 62, no. 4 (2023): e202214169.

[511] Y. Liu, F. Wang, D. Peng, et al., “Activation and Antitumor Immunity of CD8(+) T Cells Are Supported by the Glucose Transporter GLUT10 and Disrupted by Lactic Acid,” Science Translational Medicine 16, no. 762 (2024): eadk7399.

[512] J. Ma, L. Tang, Y. Tan, et al., “Lithium Carbonate Revitalizes Tumor-reactive CD8(+) T Cells by Shunting Lactic Acid Into Mitochondria,” Nature Immunology 25, no. 3 (2024): 552–561.

[513] K. M. Perrott, C. D. Wiley, P. Y. Desprez, and J. Campisi, “Apigenin Suppresses the Senescence-associated Secretory Phenotype and Paracrine Effects on Breast Cancer Cells,” GeroScience 39, no. 2 (2017): 161–173.

[514] Q. Hu, J. Peng, L. Jiang, et al., “Metformin as a Senostatic Drug Enhances the Anticancer Efficacy of CDK4/6 Inhibitor in Head and Neck Squamous Cell Carcinoma,” Cell Death & Disease 11, no. 10 (2020): 925.

[515] S. di Martino, C. A. Amoreo, B. Nuvoli, et al., “HSP90 inhibition Alters the Chemotherapy-driven Rearrangement of the Oncogenic Secretome,” Oncogene 37, no. 10 (2018): 1369–1385.

[516] S. Liu, H. Uppal, M. Demaria, P. Y. Desprez, J. Campisi, and P. Kapahi, “Simvastatin Suppresses Breast Cancer Cell Proliferation Induced by Senescent Cells,” Scientific Reports 5 (2015): 17895.

[517] H. Hu, Q. Wang, D. Yu, et al., “Berberine Derivative B68 Promotes Tumor Immune Clearance by Dual-Targeting BMI1 for Senescence Induction and CSN5 for PD-L1 Degradation,” Advanced science (Weinheim) 12, no. 7 (2025): e2413122.

[518] H. J. Hwang, D. Kang, J. Shin, et al., “Therapy-induced Senescent Cancer Cells Contribute to Cancer Progression by Promoting Ribophorin 1-dependent PD-L1 Upregulation,” Nature Communications 16, no. 1 (2025): 353.

[519] S. Giunco, M. R. Petrara, F. Bergamo, et al., “Immune Senescence and Immune Activation in Elderly Colorectal Cancer Patients,” Aging (Albany NY) 11, no. 11 (2019): 3864–3875.

[520] J. Ye and G. Peng, “Controlling T Cell Senescence in the Tumor Microenvironment for Tumor Immunotherapy,” Oncoimmunology 4, no. 3 (2015): e994398.

[521] X. Liu, D. F. Hoft, and G. Peng, “Senescent T Cells Within Suppressive Tumor Microenvironments: Emerging Target for Tumor Immunotherapy,” Journal of Clinical Investigation 130, no. 3 (2020): 1073–1083.

[522] M. Hu, M. Zhou, X. Bao, et al., “ATM Inhibition Enhances Cancer Immunotherapy by Promoting mtDNA Leakage and cGAS/STING Activation,” Journal of Clinical Investigation 131, no. 3 (2021): e139333.

[523] R. Sigaud, L. Rosch, C. Gatzweiler, et al., “The First-in-class ERK Inhibitor ulixertinib Shows Promising Activity in Mitogen-activated Protein Kinase (MAPK)-driven Pediatric Low-grade Glioma Models,” Neuro-Oncology 25, no. 3 (2023): 566–579.

[524] A. R. Moore, S. C. Rosenberg, F. McCormick, and S. Malek, “RAS-targeted Therapies: Is the Undruggable Drugged?,” Nature Reviews Drug Discovery 19, no. 8 (2020): 533–552.

[525] X. F. Bai, J. C. Ma, C. Zhang, et al., “Click Chemistry-Assisted Rejuvenation of Aging T Cells Sensitizes Aged Mice to Tumor Immunotherapy,” Journal of the American Chemical Society 147, no. 19 (2025): 16694–16704.

[526] Y. Wan, J. Wang, M. Chen, et al., “Dual Roles of IRE1α Inhibition in Reversing Mitochondrial ROS-induced CD8(+) T-cell Senescence and Exerting Direct Antitumor Effects in Multiple Myeloma,” Journal for ImmunoTherapy of Cancer 13, no. 5 (2025): e011044.

[527] J. Li, D. Huang, B. Lei, et al., “VLA-4 Suppression by Senescence Signals Regulates Meningeal Immunity and Leptomeningeal Metastasis,” Elife 11 (2022): e83272.

[528] A. Lanna, B. Vaz, and C. D'Ambra, “An Intercellular Transfer of Telomeres Rescues T Cells From Senescence and Promotes Long-term Immunological Memory,” Nature Cell Biology 24, no. 10 (2022): 1461–1474.

[529] D. M. Matthe, O. M. Thoma, T. Sperka, M. F. Neurath, and M. J. Waldner, “Telomerase Deficiency Reflects Age-associated Changes in CD4+ T Cells,” Immunity & Ageing 19, no. 1 (2022): 16.

[530] S. T. Parish, J. E. Wu, and R. B. Effros, “Sustained CD28 Expression Delays Multiple Features of Replicative Senescence in human CD8 T Lymphocytes,” Journal of Clinical Immunology 30, no. 6 (2010): 798–805.

[531] M. F. Sanmamed, F. Pastor, A. Rodriguez, et al., “Agonists of Co-stimulation in Cancer Immunotherapy Directed against CD137, OX40, GITR, CD27, CD28, and ICOS,” Seminars in Oncology 42, no. 4 (2015): 640–655.

[532] Q. Liu, Y. Zheng, J. J. Goronzy, and C. M. Weyand, “T Cell Aging as a Risk Factor for Autoimmunity,” Journal of Autoimmunity 137 (2023): 102947.

[533] E. Terrabuio, E. Zenaro, and G. Constantin, “The Role of the CD8+ T Cell Compartment in Ageing and Neurodegenerative Disorders,” Frontiers in Immunology 14 (2023): 1233870.

[534] V. Pucino, M. Bombardieri, C. Pitzalis, and C. Mauro, “Lactate at the Crossroads of Metabolism, Inflammation, and Autoimmunity,” European Journal of Immunology 47, no. 1 (2017): 14–21.

[535] A. Llibre, S. Kucuk, A. Gope, M. Certo, and C. Mauro, “Lactate: A Key Regulator of the Immune Response,” Immunity 58, no. 3 (2025): 535–554.

[536] L. Liu, X. Yue, Z. Sun, et al., “Senolytic Elimination of Senescent Macrophages Restores Muscle Stem Cell Function in Severely Dystrophic Muscle,” Aging (Albany NY) 14, no. 19 (2022): 7650–7661.

[537] A. Guerrero, N. Herranz, B. Sun, et al., “Cardiac Glycosides Are Broad-spectrum Senolytics,” Nature Metabolism 1, no. 11 (2019): 1074–1088.

[538] M. Colucci, S. Zumerle, S. Bressan, et al., “Retinoic Acid Receptor Activation Reprograms Senescence Response and Enhances Anti-tumor Activity of Natural Killer Cells,” Cancer Cell 42, no. 4 (2024): 646–661. e9.

[539] D. McHugh, I. Durán, and J. Gil, “Senescence as a Therapeutic Target in Cancer and Age-related Diseases,” Nature Reviews Drug Discovery 24, no. 1 (2025): 57–71.

[540] B. Wang, J. Han, J. H. Elisseeff, and M. Demaria, “The Senescence-associated Secretory Phenotype and Its Physiological and Pathological Implications,” Nature Reviews Molecular Cell Biology (2024).

[541] A. Georgilis, S. Klotz, C. J. Hanley, et al., “PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells,” Cancer Cell 34, no. 1 (2018): 85–102. e9.

[542] K. Tighanimine, J. A. Nabuco Leva Ferreira Freitas, I. Nemazanyy, et al., “A Homoeostatic Switch Causing Glycerol-3-phosphate and Phosphoethanolamine Accumulation Triggers Senescence by Rewiring Lipid Metabolism,” Nature Metabolism 6, no. 2 (2024): 323–342.

[543] H. Liu, Q. Xu, H. Wufuer, et al., “Rutin Is a Potent Senomorphic Agent to Target Senescent Cells and Can Improve Chemotherapeutic Efficacy,” Aging Cell 23, no. 1 (2024): e13921.

[544] A. Shahbandi, F. Y. Chiu, N. A. Ungerleider, et al., “Breast Cancer Cells Survive Chemotherapy by Activating Targetable Immune-modulatory Programs Characterized by PD-L1 or CD80,” Nature Cancer 3, no. 12 (2022): 1513–1533.

[545] B. I. Pereira, O. P. Devine, M. Vukmanovic-Stejic, et al., “Senescent Cells Evade Immune Clearance via HLA-E-mediated NK and CD8(+) T Cell Inhibition,” Nature Communications 10, no. 1 (2019): 2387.

[546] N. Rivera, A. Boada, M. I. Bielsa, et al., “Hair Repigmentation during Immunotherapy Treatment with an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer,” JAMA Dermatol 153, no. 11 (2017): 1162–1165.

[547] S. Chaib, J. A. López-Domínguez, M. Lalinde-Gutiérrez, et al., “The Efficacy of Chemotherapy Is Limited by Intratumoral Senescent Cells Expressing PD-L2,” Nature Cancer 5, no. 3 (2024): 448–462.

[548] G. Morad, B. A. Helmink, P. Sharma, and J. A. Wargo, “Hallmarks of Response, Resistance, and Toxicity to Immune Checkpoint Blockade,” Cell 185, no. 3 (2022): 576.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.